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1 REVIEW OF THE LITERATURE 
1.1 G-protein coupled receptors (GPCR) 
1.1.1 About GPCRs in general 
 Cell surface receptors are specialized integrated membrane (in most of the cases 
transmembrane) proteins, which take part in the communication between the cell’s intra- and 
extracellular environments by sensing different types of extracellular signaling molecules. 
The molecule sensing initiates with the binding of the “first messenger” molecule (ligand) to 
the receptor, which triggers chemical alterations in the intracellular side of the cell. These 
chemical changes are called signal transduction and it is an essential biological process for the 
cell to maintain its own homeostasis, cellular activity or even the communication between 
other cells if possible. Among the cell surface transmembrane proteins the G-protein coupled 
receptors (GPCR) are one of the largest and diversified, encoded by more than 800 genes in 
the human genome 
1
. GPCRs are only present in eukaryotic cells, mostly widespread within 
the Metazoa (animals) kingdom 
1–3
. According to the GRAFS classification system 
1
 there are 
five main families within the GPCR superfamily: the glutamate (15 members), the rhodopsin-
like (701 members), the adhesion (24 members), the frizzled/taste (24 members) and finally 
the secretin-like receptor family (15 members). One of the remarkable features of the GPCR 
superfamily is the large variety of extracellular signals that the receptors can detect, such as 
photons, odorants, ions, small organic molecules like lipids, catecholamines, as well as 
neuropeptides and the larger glycoproteins 
4,5
. Because of the vast diversity of GPCRs they 
have a crucial role in numerous regulatory processes in physiological as well as in 
pathological conditions, which makes this receptor superfamily a very promising 
pharmacological target 
6–9
. The importance of GPCRs is also emphasized by the fact that the 
2012 Nobel Prize in Chemistry was awarded "for studies of G-protein-coupled receptors" by 
the work of Brian Kobilka and Robert Lefkowitz (Fig. 1E; see web reference 
A
). 
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Figure 1 A and B: The side and extracellular view of the 3D crystal structure of the 
2AR-Gs protein complex together with the 2AR agonist BI-1617107. The figures were 
constructed with Chimera 
10
, (a program for interactive visualization) based on the protein data bank 
ID of the receptor-ligand complex (PDBP ID: 3SN6). C: The schematic 2D structural view of 
the 2AR-Gs protein complex viewed along the lipid bilayer. The blue cylinders indicate the 
transmembrane helixes numbered as 1-7, and the 8th helix (8) is also represented transparently. The 2D 
figure also highlights the lipid anchors of the receptor (palmitate 
11
), the G (myristate/palmitate 
11
) 
and the G (isoprenylate 
11
). ‘α’, ‘β’ and ‘’ indicates the G-protein subunits. The schematic structure 
of the heterotrimeric G-protein was constructed according to the review of Oldmann and Hamm 
12
, 
with modifications. D: The spectrum of GPCR ligand efficacy. The figure was constructed 
according to the review of Rosenbaum and co-workers 
4
 with modifications. E: Brian Kobilka 
(left) and Robert Lefkowitz (right). They received the 2012 Nobel Prize in Chemistry "for 
studies of G-protein-coupled receptors". Abbreviations: 2AR: 2-adrenergic receptor, ECL: 
extracellular loop, ICL: intracellular loop, TM: transmembrane domains. 
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1.1.2 The structure of GPCRs 
 In the past 12 years the number of solved GPCR crystal structures has grown 
exponentially, owing to innovative crystallography methods and protein engineering 
techniques 
13,5
. Today more than 75 GPCR crystal structures of 18 different rhodopsin-like 
GPCRs have been determined 
5
, including notable GPCRs like rhodopsins, β-adrenoreceptors, 
dopamine and also opioid receptors. 
 The structure of all members of the GPCR superfamily can be divided into three parts 
5,14 
(Fig 1A-C): (1) the extracellular region, containing the N terminus and three extracellular 
loops (ECL1-ECL3); (2) the transmembrane (TM) region, consisting seven α-helices (TM1-
TM7) and finally (3) the intracellular region, consisting of three intracellular loops (ICL1-
ICL3), an intracellular amphipathic helix (H8), and the C terminus. Overall the extracellular 
region modulates ligand access; the TM region forms the structural core of the receptor, binds 
ligands which then induce conformational changes in the TM region 
5
. This information is 
transmitted to the intracellular region which associates with cytosolic signaling proteins, most 
of all G-proteins (Fig 1A-C), but GPCR kinases, arrestins can also interact with GPCRs. 
1.1.3 The spectrum of GPCR ligand efficacy and constitutive activity of GPCRs 
There are several intermediate structure states of GPCRs, which are stabilized by 
distinct ligands
 15–17
. The agonist type ligands stabilize the active conformational state of the 
GPCR 
15
, which then allows the receptor to alter the G-proteins conformation to the active 
(GTP-bound; see section  1.1.4) state. In contrast, inverse agonists stabilize the inactive state 
of the receptor, in which the G-protein remains in the inactive state (GDP bound state; see 
section  1.1.4; 18,19). At the same time neutral antagonists are believed to bind equally to both 
receptor states, usually with a high affinity, thus possessing a physiological role by 
competitively inhibiting agonist and inverse agonist binding 
18,19
. Accordingly there is a 
spectrum of efficacies of GPCR ligands initiating from the full and partial inverse agonists, 
through neutral antagonists to partial and full agonists 
18
 (Fig 1D). However there is 
increasing number of evidence showing that GPCRs still have low activity in the absence of 
an agonist ligand, thus they possess a constitutive or basal activity 
18,19
. Agonists increase, 
inverse agonists decrease, while neutral antagonists do not alter GPCR basal activity. 
Interestingly in absence of basal receptor activity inverse agonists behave as competitive 
antagonist 
20
, which explains why many of the compounds originally described as neutral 
 4  
 
 
 
antagonists, turned out to be inverse agonists 
18
.  Inverse agonism is a relatively new 
phenomenon, and according to increasing numbers of studies it has a potential therapeutic 
application against cancer 
20
 and other human diseases 
21–24
. Rimonabant, one of the 
protagonist of this thesis is an inverse agonist too, and it will be discussed under section  1.3. 
1.1.4 GPCR signaling: the G-protein activation/deactivation cycle  
 Heterotrimeric G-proteins are often called molecular switches, since they can initiate 
and terminate intracellular signaling cascades generated by GPCRs during extracellular 
stimuli. G-proteins consist of three subunits: , β and γ, where the G is the “main switch” 
and the only G-protein subunit making direct contact with the receptor, while Gβ and Gγ form 
a functional unit, and can only be dissociated in denaturing conditions 
25
. The key to the 
mediatory role of G is its GTP/GDP binding ability and GTPase (GTP hydrolyzing) activity. 
After agonist-mediated conformational change of the receptor, the assumed pre-
associated G-protein 
26
 also switches to the active conformational state, which allows the G 
subunit to exchange the already bound GDP to GTP (Fig. 2, step 2). The nucleotide exchange 
process then promotes the heterotrimeric complex to dissociate from the receptor and to 
divide to G and Gβ subunits, which afterwards interact with distinct effector molecules 
separately (Fig. 2, step 3). The effectors can be enzymes such as adenylyl cyclase, or 
phospholipases, and they can also be ion channels like G-protein-activated inwardly rectifying 
K
+
 channels. Eventually the G subunit will hydrolyze the bound GTP back to GDP (Fig. 2, 
step 4), due to its intrinsic GTPase activity, restoring the initial state by re-associating with the 
Gβ subunit and starting a new cycle 
12,27,28
 (Fig. 2, step 4). The G-protein 
activation/deactivation cycle can be studied by the [
35
S]GTPS binding assay which will be 
discussed in detail under section  3.5.3. 
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Figure 2 The G-protein activation/deactivation cycle. For detailed description see 
section  1.1.4. Note the higher levels of GTP in step 2 compared to GDP, this is to insure the GDP/GTP 
exchange 
12
. The hydrolyzed free phosphate ion is referred to as inorganic phosphate; this is to 
distinguish it from bound phosphates. The basis of the figure was constructed according to the 
following figure: http://en.wikipedia.org/wiki/File:GPCR_cycle.jpg. The [35S]GTPS binding assay is 
illustrated under Fig. 7 with similar symbols. 
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1.1.5 The complexity of GPCR signaling    
From the 23 encoded human G proteins four G-protein classes has been described: 
Gs, Gi/o, Gq/11 and  G12/13 (in case of β and γ there are 6 and 12 G-protein classes) and they 
can interact with different types of effectors or they can alter their function differently 
29
. 
Stimulation of the Gs subunit activates adenylyl cyclase (AC; 
30
), while stimulation of the 
Gi/o subunit results AC inhibition 
31
. Inducing Gq/11 activates phospholipase C (PLC; 
32
) 
whereas G12/13 is involved in the regulation of cell growth 
33
. Additionally Gi/o and Gs 
subunits can go through ADP-ribosylation catalyzed by pertussis (produced by Bordetella 
pertussis) and cholera toxins (produced by the Vibrio cholerae) respectively 
12,34
. The ADP-
ribosylation prevents both G-proteins to function normally, resulting altered AC activity 
levels compared to normal levels.    
The relatively few types of G-protein compared to the vast number of GPCR 
subfamilies results that G-proteins can interact with many different types of GPCRs, and also 
many receptors can activate different types of G-protein signaling pathways 
12
. The 
complexity of GPCR signaling is augmented by the large GPCR binding surface of the G-
protein 
12
 which enables it to interact with multiple GPCRs simultaneously. Moreover 
receptor homo-, and heterodimerization, or even oligomerization is a common phenomenon in 
the GPCR superfamily 
35–37
. Thus it is not surprising that GPCRs can cross-regulate each 
other’s signaling pathways, communicate with one and other, altering each other’s 
physiological responses 
29,38–41
. Also there is an emerging concept in GPCR signaling referred 
to as “biased agonism” or “ligand-directed signaling”, which declares that distinct agonists 
can initiate different active receptor conformational states, which in turn initiates distinct 
signaling pathways 
20,42,43
. 
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1.2 Opioids and cannabinoids and their endogenous systems    
1.2.1 Opium poppy and the cannabis plant, opioids and cannabinoids 
The usage of the opium poppy (Papaver somniferum; Fig. 5A) and the cannabis plant 
(Cannabis sativa, Cannabis indica, Cannabis ruderalis; Fig. 5B) as an agricultural plant, 
medicine or as a recreational drug dates back to ancient history 
44,45
. Opium and marijuana are 
the most known and used recreational drugs derived from the plants. Opium is the dried latex 
extracted from the ripening pods of the poppy (Fig. 5A), while marijuana is the dried flowers 
and leafs of the female cannabis plant 
44,45
. Opium is known for its anesthetic, euphoric and 
narcotic effects, accompanied by strong withdrawal and addictive effects, while marijuana 
causes relaxation, increases the appetite and also enhances the enjoyment of tastes, sounds 
and smells 
44,45
. The main psychoactive compound of the opium and marihuana is morphine 
(Fig. 5C)  and 9tetrahydracannabinol (THC; Fig. 5D) respectively 44,45. Apart from morphine 
and THC, there are several other opium poppy and cannabis plant-derived molecules, together 
with semi- and fully synthetic derivatives which are all together called opioids and 
cannabinoids respectively (Fig. 5C and D). Today a lot of effort is being invested into the 
research of these molecules to maintain or increase the benefits of their natural derivatives 
while reducing their disadvantages so they can be applied safely for therapeutics.  
1.2.2 Opioid and cannabinoid receptors 
Opioids and cannabinoids have their specific endogenous receptors: the opioid 
46–48
 
and the cannabinoid receptors 
49–51 
(Fig. 3). Three types of opioid receptors have been 
determined: µ-,- and -opioid receptors 52–56 (MOR, KOR, DOR respectively; Fig. 3), which 
were later supplemented by the nociceptin receptor 
57
. However the nociceptin receptor is still  
 
Figure 3 Milestones in opioid and cannabinoid research I. The figure is loosely based 
on the figure in review 
44
 . 
46–48
, 
58
, 
49–51
, 
59
, 
60
, 
52–56
  
46–48 49–51 
52–56 59 58 
60 
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Figure 4 Milestones in opioid and cannabinoid research II. The figure is loosely based 
on the figure in review 
44
.61, 62, 63, 64, 65  
being treated separately from “the three classic” opioid receptors, because the semi-synthetic 
neutral opioid antagonist, naloxone  cannot inhibit nociceptin receptor specific binding, unlike 
the other three opioid receptors binding 
45
. The cannabinoid receptor family has two types the 
type 1 and 2
 
cannabinoid receptors 
59,61
 (CB1, CB2; Fig. 3 and 4), and recently the G-protein 
coupled receptor 55 along with 119 and 18 (also known as GPR55, GPR119 and GPR18 
respectively) are also believed to be cannabinoid receptors 
66,67
. 
Both cannabinoid and opioid receptors belong to the  GPCR super family and they 
mostly couple to Gi/o type G-proteins 
68,69
, thus they inhibit AC activity 
70,71
, decrease 
calcium ion entry 
69,72
 and increase potassium ion efflux 
69,73
, which in turn inhibit the 
presynaptic release of different types of neurotransmitters such as GABA, noradrenaline, 
acetylcholine or dopamine 
74,75
. The cellular actions add up to several important physiological 
functions which are listed in Table I together with the receptors central and peripheral 
distribution. Important to note that the CB1 receptor is the most abundant GPCR in the brain, 
with ten times higher expression levels compared to other GPCRs.  
1.2.3 The endogenous opioid and the endocannabinoid system 
Besides endogenous opioid and cannabinoid receptors, endogenous opioid and 
cannabinoid ligands (or endocannabinoids) have also been identified (Fig. 5C and D).  
Endogenous opioids are peptide natured neurotransmitters, neuromodulators or even 
neurohormones 
76,77
, and the most notable ones are the enkephalins 
58
 (Fig. 3), endorphins 
78
, 
dynorphins 
79
, nociceptin 
80
 and endomorphins 
81
. The endocannabinoids behave as 
neuromodulators, and are arachidonic acid derivatives 
82,83
, such as the arachidonoyl 
ethanolamide (anandamide; Fig. 4) 
60
, 2-arachidonoylglycerol 
84
 or noladin ether 
85
. The 
endogenous opioids are synthesized from precursor proteins (prepro-opiomelanocortin, 
62 64 
65 61 63 
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preproenkephalin and preprodynorphin) 
86,87
, while the endocannabinoids are cleaved from 
phospholipid membranes or synthesized through the fatty acid synthesis 
83
. These systems 
which comprise the enzymes which synthesize and degrade endogenous opioids and 
endocannabinoids, together with the receptors, which recognize them, are called the 
endogenous opioid and endocannabinoid system. Both systems are under strict regulation 
83,88
, 
however main difference is that the endocannabinoids are not synthesized in advance and 
stored in vesicles compared to endogenous opioids 
89 
or other neuromodulators, instead they 
are released “on demand” 82,83,90,91. 
 
Figure 5 A: The capsule of the opium poppy (Papaver somniferum). The picture shows 
the capsule after a fresh incision, with the exuded latex-like raw opium. B: Female flowering 
cannabis plant (Cannabis indica). Note the small crystals on the flower, which are highly 
concentrated with THC. C: Opioids. From left to right: morphine (plant derived opium alkaloid), 
met-enkephalin (endogenous) and fentanyl (fully synthetic). D: Cannabinoids. From left to right: 
THC (plant derived or phytocannabinoid), anandamide (endocannabinoid) and WIN 55,212-2 (fully 
synthetic). Chemical structures were downloaded from http://www.ncbi.nlm.nih.gov/pccompound/. 
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1.2.4 Opioid and cannabinoid receptor interactions 
 It is known that the expression patterns of cannabinoid and opioid receptors overlaps 
in several parts of the CNS (see Table I). In certain forebrain regions, such as caudate 
putamen, dorsal hippocampus, substantia nigra, and nucleus accumbens, the MOR and CB1 
receptors are not only co-localized, but also co-expressed in the same neurons 
92–94
. It has also 
been shown that these two receptors can be cross-regulated 
95
 via a direct 
96 
or indirect 
interactions 
29,97
, and they can also form heterodimers 
98
. The CB1 and DOR together with 
KOR can too allosterically alter each other’s activity 97,99–101 and in case of DOR can form 
heteromers as well 
101
. The interaction between these receptors results many overlapping 
physiological functions such as nociception 
101–105
, mood regulation 
106,107
, energy and feeding 
regulation 
108,109
, regulation of GI motility 
110
 or the mediation of ethanol effects 
111
. There is 
also evidence for an interaction between the CB2 and MOR in the mouse forebrain and 
brainstem, which was demonstrated by our group 
112,113
. However the interaction between 
opioid and CB2 receptors needs more detailed studies. 
Table I The distribution and physiological effects of opioid and cannabinoid receptors 
 
* denotes the CNS regions where opioid and CB1 receptors are proved to interact with each other and 
are co-expressed. The table was constructed based on the following publications: 
45,74–76,83,102,114–116
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1.3 Rimonabant 
1.3.1 The CB1 receptor and appetite, Acomplia®  
 Increased hunger has been long associated with Cannabis use 
117–119
, also there is 
extensive evidence that the endocannabinoid system, especially the CB1 receptor is involved 
in the control of appetite and feeding (for review see 
120
). 
 SR141716, or rimonabant (Fig. 6A) was developed as a highly selective CB1 
antagonist, sponsored by Sanofi Aventis (now Sanofi S.A.) 
62
, with a Ki of 5.6 nM towards its 
specific receptor. For comparison, rimonabant binds to CB2 receptors with >1000 nM Ki. 
Rimonabant can effectively antagonize most of the effects of different types  of CB1 agonist 
both in vivo and in vitro 
116,121 
and according to preclinical animal, and clinical human studies 
showed a clear efficacy for the treatment of obesity (for review see: 
122,123
).  In 2006 The 
European Commission approved the sale of rimonabant in the European Union and was first 
introduced in the United Kingdom under the trade name Acomplia® (Fig. 6B).  
 The weight-loss effect of rimonabant is believed to be mostly accomplished through 
the peripheral CB1 receptors on adipocytes and hepatocytes, by decreasing lipogenesis (for 
review see: 
120,124
). Rimonabant is also able to pass through the blood-brain-barrier (BBB) 
121
, 
therefore it can interact with CB1 receptors expressed in brain areas which are implicated in 
the reinforcing effects of natural reinforces such as food (for review see: 
120,124
). 
1.3.2 The psychiatric side effects and unspecific actions of rimonabant 
 Interacting with CB1 receptors that are working together with the reinforcing/reward 
system might result unspecific actions of rimonabant. Indeed according to Christensen and 
colleagues 
125 
during the clinical trials patient were experiencing psychiatric pathographies 
such as anxiety, depression, mood alterations or suicidal thoughts during 20 mg rimonabant 
treatment. The psychiatric side effects were also affirmed by the United State Food and Drug 
Administration’s (FDA) briefing document (see web reference B), which led to the 
disapproval of rimonabant marketing authorization in the US. These findings were culminated 
when four patients committed suicide in the rimonabant group during the study period, which 
resulted the withdrawal of rimonabant in 2008 by the European Medicines Agency (see web 
reference 
C
). 
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 Many studies revealed that rimonabant can produce effects opposite to cannabinoid 
agonist in vivo and in vitro, that is it can behave as an inverse agonist (see section, for review 
see 
123
). It is also believed that its anorectic effect is due this pharmacological property 
120,124
. 
Additionally, before as well as after entering rimonabant to the market there were several 
publications indicating its non-CB1 receptor related actions 
126,127
, partly its inverse agonistic 
effects 
126,128–130
 and its dose related side effects 
125,131,132
. These reports also established a 
rather unspecific behavior at higher concentrations (for review see 
133,134
). Yet again these 
unspecific actions can endow rimonabant with promising therapeutical applications in drug 
dependence (for review see 
135
). 
 
1.3.3 Interactions of rimonabant with the opioid system 
  Rimonabant can interact with other members of the GPCR family, such as opioid 
receptors (for review see 
134
). It has been shown that it can affect the function of MOR 
through the CB1 receptor (for review see 
135,136
), additionally when studied in behavioral 
aspects rimonabant reduced opiate self-administration and reward 
137–139
 and suppress 
morphine-induced feeding 
140
. There are increasing numbers of studies reporting a direct 
effect of rimonabant on opioid receptors. According to previous direct binding affinity 
measurements rimonabant is able to bind to all three classic opioid receptors with a relatively 
high, micromolar concentrations 
128,141,142
. It has been also demonstrated that KOR agonist 
ligand potency can be reduced by rimonabant in vitro during agonist-stimulated KOR G-
protein activation 
143
. Additional in vitro assays also excluded a possible allosteric modulatory 
effect of rimonabant on MOR and DOR 
142
.  Furthermore, Lockie and co-workers revealed 
that the opioid system is involved in modulating both the metabolic and mood effects of 
rimonabant 
144
. 
Also many studies described the effectiveness of combined rimonabant and opioid 
antagonist treatment. For instance the combination of low dose rimonabant with low dose 
naloxone/naltrexone can reduce food intake and ethanol intake more effectively than 
administrating them separately in similar doses (for review see 
145,146
).  
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Figure 6 A: The structure of rimonabant. Systematic name: 5-(4-Chlorophenyl)-1-(2,4-
dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide. The chemical structure 
of rimonabant was downloaded from http://www.ncbi.nlm.nih.gov/pccompound/. B: 
Acomplia® packaging containing 20 mg rimonabant.  
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2 AIMS OF THE STUDY 
The unspecific behaviour of rimonabant together with its ability to pass through the 
BBB partly caused its dramatic failure as an authorized anorectic drug (see section ‎1.3.2). 
Additionally the CB1 receptor is the most widespread GPCR in the brain integrated in 
different types of neurological pathways such as dopamine pathways 
147
, which can also 
explain the psychiatric side effects of rimonabant. 
  Now it is known that the opioid receptors are also expanded to the unspecific actions 
of rimonabant (see section ‎1.3.3). Most of the studies examining the actions of CB1 antagonist 
on opioid receptors are reported to be mediated through CB1 receptors, but very few studies 
examine the direct effect of rimonabant on opioid receptors. Herein we clarify whether 
rimonabant can interact with MOR and DOR directly at the level of ligand-receptor and 
receptor-G-protein interaction. MOR was chosen because it is one of the most studied opioid 
receptors, mainly because of their  role in pain management 
148
. The DOR is relatively studied 
in a less extent compared to its two other companions, especially to MOR 
149
. However, 
recently there are several studies showing DOR as a potential therapeutic target (for review 
see 
150
). This thesis is part of an overall study, which also investigates the possible direct 
effect of rimonabant on KOR, however due to page limitations only selections of the results 
are presented here 
151,152
. 
The aims of the study presented in this thesis were the following: 
 To measure the binding affinity of rimonabant towards MOR and the role of the CB1 
receptor in the binding in competition binding assays with MOR specific radioligands 
performed in wild type and CB1 knock-out forebrain membranes and in Chinese hamster 
ovary (CHO) cell membranes overexpressed with rat MORs (CHO-rMOR). 
 To characterize the binding capacity of rimonabant on DOR in competition binding assays 
carried out with DOR specific radioligands accomplished in CHO cell membranes 
overexpressed with mouse DORs (CHO-mDOR). 
 To dock rimonabant into the active and inactive homology model of MOR and also to 
analyze the docking energies and poses of the compound in docking experiments 
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  To investigate the effect of rimonabant on DOR mediated G-protein activity in functional 
[
35S]GTPγS binding assays carried out in CHO-mDOR membranes. 
 To analyze the impact of rimonabant on DOR mediated G-protein activity after agonist 
stimulation in functional [
35S]GTPγS binding assays accomplished in CHO-mDOR 
membranes. 
 To examine the effect of rimonabant on agonist-stimulated MOR and DOR G-protein 
activity and the possible role of cannabinoid receptors in the observed actions in the 
forebrain region in [
35S]GTPγS binding assays carried out in wild type and CB1 or 
CB1/CB2 knock-out  mouse forebrain membranes.  
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3 MATERIALS AND METHODS 
3.1 Chemicals 
3.1.1 Radiochemicals 
[
3
H]DAMGO (specific activity: 41 Ci/ mmol), [
3
H]naloxone (specific activity: 31 Ci/ 
mmol) and 3HIle5,6deltorphin II (specific activity: 28 Ci/mmol; 153) was radiolabeled in the 
Isotope Laboratory of BRC (Szeged, Hungary). [
3
Hnaltrindole (specific activity: 
24 Ci/mmol) was purchased from PerkinElmer (Boston, USA). The radiolabelled GTP 
analogue, [
35S]GTPγS (specific activity: >1000 Ci/mmol) was purchased from the Isotope 
Institute Ltd. (Budapest, Hungary). 
3.1.2 Receptor ligands and fine chemicals 
 The CB1 receptor antagonist SR141716 (rimonabant) was acquired from Santa Cruz 
(Dallas, Texas, USA) and was also provided by SANOFI Research Laboratory (Montpellier, 
France). The enkephalin analog Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol (DAMGO) was obtained 
from Bachem Holding AG (Bubendorf, Switzerland). The MOR agonist morphine was 
obtained from the Alkaloid Chemical Factory (Tiszavasvári, Hungary). The modified DOR 
specific deltorphin II derivative, Ile
5,6
deltorphin II was synthesized in the Isotope Laboratory 
of Biological Research Center (Szeged, Hungary). The DOR specific agonist peptide 
[D-Pen
2,5
]-enkephalin hydrate (DPDPE), the DOR antagonist naltrindole, the KOR specific 
agonist U50488 and the adrenerg receptor agonist L-epinephrine were purchased from Sigma-
Aldrich (St. Louis, MO, USA). The opioid antagonist naloxone was kindly provided by the 
company Endo Laboratories DuPont de Nemours (Wilmington, DE, USA). Ligands were 
dissolved in ultrapure distilled water, except rimonabant which was dissolved in DMSO. All 
applied receptor ligands were stored in 1 mM stock solution at -20 ˚C. Tris-HCl, EGTA, 
NaCl, MgCl2 x 6H2O, GDP, the GTP analogue GTPγS were obtained from Sigma-Aldrich 
(St. Louis, MO, USA). The UltimaGold
TM
 MV aqueous scintillation cocktail was purchased 
from PerkinElmer (Boston, USA).  
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3.2 Animals 
The CB1 receptor knockout (CB1 K.O.) mice and their wild type controls (w.t.) were 
generated on CD1 background in Dr. Ledent‘s lab as described in Ledent et al., 1999 154. The 
CB1

/ CB2 receptor double knockout mice were provided by Dr. Andreas Zimmer’s laboratory 
(University of Bonn, Germany), the lack of both cannabinoid receptors was confirmed in 
previous studies 
63
. The wild type mice were bought from the local animal house of the 
Biological Research Center (Szeged, Hungary). Both mice genotypes were derived from the 
C57BL/6J strain. For membrane preparations 6-8 animals were used. All the animals were 
housed at 21-24 ˚C under a 12:12 light: dark cycle and were provided with water and food ad 
libitum. All housing and experiences were conducted in accordance with the European 
Communities Council Directives (86/609/ECC) and the Hungarian Act for the Protection of 
Animals in Research (XXVIII.tv. 32.§). 
3.3 Cell lines 
Chinese hamster ovary cells (CHO) stably transfected with rat MOR or mouse DOR 
cDNA (CHO-rMOR and CHO-mDOR respectively) were provided by Dr. Zvi Vogel 
(Weizmann Institute of Science, Israel). The cell lines were previously characterized by 
Avidor-Reiss and co-workers together with Ioja and co-workers 
155–157
. Parental CHO 
(pCHO) cell lines were kindly provided by Dr. Melinda Pirity (Biological Research Center, 
Szeged, Hungary)  
CHO-rMOR and CHO-mDOR cells were grown in Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco) and in α-minimum essential medium (αMEM, Gibco), respectively. 
Both media were supplemented with 10% fetal calf serum, 2 mM glutamine, 100 IU/ml 
penicillin, 100 mg/ml streptomycin, 25 mg/ml fungizone and 0.5 mg/ml geneticin. Parental 
CHO cells (pCHO) were cultured in F-12 medium with L-glutamine which contained 10% 
fetal bovine serum. Both CHO cell lines were kept in culture at 37˚C in a humidified 
atmosphere consisting of 5% CO2 and 95% air. 
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3.4 Membrane preparations 
3.4.1 Mouse forebrain membrane preparations 
Forebrain membrane fractions from CB1 K.O. and CB1/ CB2 K.O. mice and their wild 
type controls were prepared according to the method previously described 
158
. Briefly, mice 
were decapitated and the brain was quickly removed. The forebrain part was collected and 
homogenized on ice in 50 mM Tris-HCl buffer (pH 7.4) with a Teflon-glass homogenizer. 
The homogenate was centrifuged at 18,000 rpm for 20 min at 4˚C and the pellet was 
resuspended in fresh buffer and incubated for 30 min at 37˚C. This centrifugation step was 
repeated, and in case of competition binding experiments the final pellet was resuspended in 
50 mM Tris-HCl buffer (pH 7.4) containing 0.32 M sucrose and stored at −80˚C until use. For 
[
35S]GTPγS binding assays the final pellet was suspended with ice-cold 50 mM Tris–HCl pH 
7.4, 1 mM EGTA, 5 mM MgCl2 (TEM) buffer to obtain the appropriate protein content for 
the assay (~10 g/ml). 
3.4.2 Cell line membrane preparations 
Membranes were prepared from subconfluent cultures. Cells were rinsed three times 
with PBS and kept in -80 ˚C for one hour. Afterwards the cells were centrifuged at 3000 rpm 
for 10 minutes. The cells were then suspended in either 50mM Tris-HCl (for competition 
binding experiments) or TEM (for [
35S]GTPγS binding assays) buffer and homogenized with 
glass/glass homogenizer in ice-bath. Homogenates were centrifuged two times at 18.000 rpm 
for 20 minutes. The final pellet was resuspended in TEM buffer and stored in aliquots at -80 
˚C until use. 
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3.5 In vitro binding assays 
3.5.1 The principles of in vitro binding assays 
Binding assays allows us to characterize radiolabeled or unlabeled ligands and at the 
same time we can gather information about the binding capacity or even the functionality of 
an observed receptor 
159,160
. The basis of the assays is to add a radioactive compound to a 
protein homogenate, membrane fraction, cell culture etc. and then incubate them together in 
certain conditions until the equilibrium binding is reached. Afterwards the bound and free 
radioactive ligands can be separated from each other; therefore the amount of bound 
radioactive ligand can be measured. 
During the binding assays with radioactive compounds the radiolabeled molecule can 
not only bound to its own specific binding site, but also to other non-specific sites such as on 
cell membranes or other sites of the target protein. This phenomenon is called non-specific 
binding and it must be subtracted from the measured total binding. To determine the level of 
non-specific binding, the radioactive ligand must be incubated together with an unlabeled 
ligand which is highly specific to the same target protein as the radioactive compound 
(usually it is the unlabeled form of the radioactive ligand). It is important to add the unlabeled 
ligand in a much higher concentrations than the radioligand itself so that it can be surely 
“displaced” from its specific binding site by the unlabeled ligand. Accordingly the only 
detectable radioactivity is due to the non-specific binding of the radioligand. 
Important to note that in receptor binding assays a point of reference should be applied, 
which just only contains the radioactive ligand and the target protein source. This is referred 
to as total specific binding and it allows comparing when other unlabeled molecules are in the 
system. 
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3.5.2 Radioligand competition binding assays 
 The radioligand competition binding experiment is a type of binding assay, where we 
apply the radioactive ligand in fixed concentrations in the presence of increasing 
concentrations of an unlabeled ligand. If the unlabeled ligand has specificity towards the 
receptor as the radioligand, they will “compete” with each other for the same binding site and 
the unlabeled ligand will displace the radioligand in a concentration dependent manner. The 
displacement will be indicated by the reduced detected radioactivity in the sample. This way 
we can receive binding affinity information about the applied unlabeled ligand, that is why it 
is called an indirect receptor binding assay, since the informations are gathered through the 
radioligand. There are two types of radioligand competition binding experiments: homologous 
and heterologous. In homologous competition binding experiments the radioligand and the 
unlabeled competitor ligand only differ in the presence of radioactivity, while in case of 
heterologous competition binding assays the two compounds are chemically distinct as well.   
    Firstly, in case of CB1 K.O. forebrain membranes and their wild type controls the frozen 
aliquots were first centrifuged (18000 rpm, 20 min, 4˚C) to remove sucrose and the pellets, 
together with pCHO, CHO-rMOR, and CHO-mDOR membranes were suspended in 50 mM 
Tris-HCl buffer (pH 7.4) to reach the appropriate protein content for the assay (0.2-0.5 
mg/ml/tube). Membranes were incubated with gentle shaking at certain conditions depending 
on the radioligand (3HDAMGO: 35˚C for 45 min; [3H]naloxone: 0˚C for 60 min; 
3HIle5,6deltorphin II: 35˚C for 45 min; [3Hnaltrindole: 25 ˚C for 60 min). The final volume 
of the incubation mixture was 1 ml containing approximately 1 nM of radioligand and 
increasing (10
-10
 - 10
-5
 M) concentrations of unlabeled rimonabant or DAMGO or 
Ile
5,6
deltorphin II, depending on the experiment. The non-specific binding was determined in 
the presence of 10 M unlabeled naloxone. The reaction was terminated by rapid filtration 
under vacuum (Brandel M24R Cell Harvester), and washed three times with ice-cold 50 mM 
Tris-HCl (pH 7.4) buffer through Whatman GF/C (3HDAMGO,3HIle5,6deltorphin II) or 
GF/B  ([
3
H]naloxone, [
3
Hnaltrindole; which was washed in 3% polyethylenimine for 60 min 
to reduce non-specific binding) glass fiber filters. The radioactivity of the filters was detected 
in UltimaGold
TM
 MV aqueous scintillation cocktail with Packard Tricarb 2300TR liquid 
scintillation counter. The competition binding assays were performed in duplicates and 
repeated at least three times. 
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3.5.3 Functional [35S]GTPγS binding assays 
 During [
35S]GTPγS binding assays we monitor the target receptor mediated G-protein 
activation, namely the GDP → GTP exchange of G, in the presence of a certain ligand 
concentration. The nucleotide exchange is measured by a non-hydrolysable, radioactive GTP 
analogue called [
35S]GTPγS, which contains a sulphur 35 isotope (35S) in the γ phosphate 
group instead of an oxygen atom. Because of the γ-thiophosphate bound the [35S]GTPγS 
withstand the GTPase activity of G, thus it cannot hydrolyze to GDP and the G-protein 
cannot reassociate to a heterotrimer (Fig. 7, compare with  Fig. 2 and see section ‎1.1.4). As a 
consequence the G bound with [
35S]GTPγS accumulates and we can measure the 
incorporated 
35
S radioactivity in the samples (Fig. 7, step 4). If we add an agonist to the 
experimental system the receptor will be activated resulting a higher GDP → [35S]GTPγS 
exchange (Fig. 7, step 2) with higher radioactivity in the assay compared to the receptors 
basal activity (see section ‎1.1.3). In the presence of an inverse agonist (see section ‎1.1.3) the 
GDP → [35S]GTPγS exchange reaches lower levels compared to basal activity resulting lower 
radioactivity. In both cases the actions are concentration dependent. Since an antagonist does 
not alter its target receptors basal activity (see section ‎1.1.3) no difference in the nucleotide 
exchange is detected compared to basal activity. Accordingly the [
35S]GTPγS binding assay is 
capable to distinguish the binding character of a ligand, and also it can give us information 
about the target receptor mediated G-protein efficacy and the activator ligand potency (see 
section ‎3.7) Worth of note that the total specific binding (which only contains the radioactive 
molecule) in the [
35S]GTPγS binding assay also indicates the basal activity of the target 
receptors G-protein. In addition the [
35S]GTPγS binding assay is more feasible for monitoring 
Gi type G-proteins 
161
.   
The assays were performed according to previous studies 
162,163
, with slight 
modifications. Membrane fractions of pCHO, CHO-rMOR, CHO-mDOR, CB1 K.O., 
CB1/CB2 K.O. and wild type mouse forebrains were incubated in a final volume of 1 ml at 
30˚C for 60 min in Tris-EGTA buffer (pH 7.4) composed of 50 mM Tris-HCl, 1 mM EGTA, 
3 mM MgCl2, 100 mM NaCl. The incubation mixture also contained 0.05 nM [
35S]GTPγS 
and 30 M GDP together with the indicated concentrations of DAMGO, DPDPE, rimonabant, 
naltrindole, U50488, morphine or L-epinephrine. Non-specific binding was determined in the 
presence of 10 M unlabeled GTPγS. Bound and free [35S]GTPγS were separated by vacuum 
filtration through Whatman GF/B filters, otherwise the filtration process and the detection of 
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the samples were the same as described under section  3.5.2). The [35S]GTPγS binding 
experiments were performed in triplicates and repeated at least three times. 
 
Figure 7 The G-protein activation in the presence of the non-hydrolysable 
[
35
S]GTPS.  For detailed description see section  3.5.3. Note the higher levels of GDP in step 2 
compared to [35S]GTPS, this is to insure the initiation of the receptor activation. Compare this figure 
with Fig. 2. 
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3.6 Docking experiments 
Molecular docking attempts to predict the structure of an intermolecular complex 
formed between two or more molecules, such as a receptor and a ligand based on their already 
determined 3D structures (for review see 
164,165
). The prediction solves two main problems 
namely to find the precise orientation and conformation of the ligand (posing) and to calculate 
the interaction energies between the ligand and the receptor (scoring) 
164
. Docking protocols 
are a combination of a searching algorithm and a scoring function 
164
. Basically a search 
algorithm scans the conformational space for docking, while the scoring function evaluates 
the strength of intermolecular interactions between the receptor and ligand once the ligand is 
docked in a certain position 
164
. Also the scoring function distinguishes the true binding 
modes from other alternative ones and classifies which ones are most likely to interact with 
the receptor based on the established binding free energies (this process is called ranking the 
ligands) 
164
. Genetic algorithm is one of the most favored search algorithms; it applies the 
theory of genetics and biological evolution in molecular docking 
164,166
, while most scoring 
functions are physics-based molecular force fields derived from experimental work as well as 
quantum mechanical calculations (for review see 
167
).    
In our docking experiments the 3D coordinates of the active and inactive 
conformations of MOR prepared by homology modeling were downloaded from the Mosberg 
group’s webpage (see web reference D; although the homology model of MOR was prepared 
for the rat, the part of the sequence modeled was 100% identical to that of mice). The 
activated receptor model contained the MOR selective agonist, H-Tyr-c(S-Et-S)[D-Cys-Phe-
D-Pen]NH2 (JOM-6; downloaded as: OPRM_RAT_AD_JOM6), and the inactive receptor 
model contained the κ-opioid antagonist, norbinaltorphimine (nor-BNI; downloaded as: 
OPRM_RAT_ID_BNI). The 3D coordinates of rimonabant, DAMGO and naloxone were 
downloaded from the Cactus web site (see web reference 
E
) using Avogadro (see web 
reference 
F
), an open source chemical structure editor program. The embedded Openbabel 
168
 
program suite was used to energy minimize the structures with the MMFF94s 
169
 force field. 
Ligands and receptors were prepared for docking using the AutoDockTools 
170
 program suite 
and then docked by the program AutoDock4 
170
. In AutoDock, the maximum number of 
energy evaluations, the number of individuals in population and the number of Lamarckian 
Genetic Algorithm runs were 25000000, 350 and 20, respectively to achieve an exhaustive 
search for the docked poses. The size of the grid docking box was 50 Å and centered at the 
middle of the binding pocket. Each docking started with a random translation, rotation and 
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torsional modification of the ligands. The receptors were kept rigid in the docking 
calculations because the limitation in the number of the flexible torsional angles prevented to 
treat the whole binding pocket and the ligands flexible simultaneously. In addition, the 
docking calculations were repeated by using the flexible ring method, a specific feature of 
AutoDock. The calculations resulted in the estimated docking free energies in kcal/mol. 
3.7 Data analysis 
All experimental data were presented as means ± S.E.M. and if the ligands were added 
in increasing concentration they were presented in the function of the applied ligand 
concentration in a logarithmic scale. Data were fitted with the professional curve fitting 
program, GraphPad Prism 5.0 (GraphPad Prism Software Inc., San Diego, CA), using non-
linear regression. 
In the competition binding assays the inhibition of the specifically bound 
3HDAMGO,3HIle5,6deltorphin II, [3H]naloxone and 3Hnaltrindole was given in 
percentage, the total specific binding and the minimum level of non-specific binding was 
defined as 100% and 0% respectively. Data were fitted with the ‘One site competition’ or in 
the case of [
3
H]naloxone or 3Hnaltrindole displacement studies the ‘Two sites-Fit logIC50’ 
fitting equation was applied to determine the concentration of the competitor ligands that 
displaced 50% of the radioligand (IC50; Fig. 8A). The IC50 value characterizes the affinity of 
the unlabeled ligand towards the target receptor; the lower the IC50 value is, the higher the 
affinity of the unlabeled ligand towards the observed receptor, since it can produce the 50 % 
inhibition in lower concentrations. Additionally in competition binding experiments 
performed in pCHO cell membranes the bound 3HIle5,6deltorphin II was represented in cpm 
(counts per minute) since there was no specific binding observed in these experiments (see 
Fig. 10). 
In the [
35S]GTPγS binding assays the ‘Sigmoid dose-response’ fitting was used to 
determine the maximal stimulation or efficacy (Emax) of the receptors G-protein (Fig. 8B) and 
the potency (EC50) of the stimulating ligand (Fig. 8B). The EC50 value indicates the affinity 
property of the applied ligand and it is analogous to the IC50 value. Stimulation was given in 
percents of the specific [
35S]GTPγS binding observed over or under the basal activity, which 
was settled as 100%. 
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Statistical analyses were performed by GraphPad Prism 5.0. In case of two data sets 
unpaired t-test with two-tailed P value statistical analysis was used, while in the case of three 
or more data sets One-way ANOVA with Bonferroni’s Multiple Comparison post hoc test 
was performed to determine the significance level. Since both the competitor and stimulator 
ligands were presented in the logarithm form, the curve fitting program could only calculate 
S.E.M. for the logarithm form of IC50 (logIC50) and EC50 (logEC50) values. At the same time 
their antilogarithm form were also shown in the figures for better understanding. Significance 
was accepted at the P < 0.05 level. 
During docking experiments the lowest docking free energies obtained were used to 
rank the ability of the ligands to bind to the receptor. Additionally, the energy balance of the 
receptor activation process was calculated for each ligand, subtracting the docking energy of 
the ligand-active receptor complex from that of the ligand-inactive receptor complex 
(“receptor activation energy”). This value was used to characterize the agonistic-antagonistic 
nature of rimonabant. The docking poses of rimonabant were analyzed and visualized by the 
program Chimera 
10
. 
 
Figure 8 A: The parameters of competition binding curves. B: The parameters of 
sigmoid dose-response curves of [
35
S]GTPS binding assays. The important parameters such 
as logIC50, Emax and logEC50 are indicated in bold; the other parameters are also represented because 
they are necessary for the calculations of logIC50 or logEC50 values. “Total” and “Basal” on the X axis 
refers to the points which did not contain unlabeled ligands only the radioactive compounds and also 
represents the total specific binding of the radioactive molecule or the basal activity of the receptor 
(B). The gap in the X-axis indicates the scale between the most diluted point and the point where no 
unlabeled ligands were added (“Total” and “Basal”). For more details see section  3.7. 
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4 RESULTS 
4.1 Direct binding affinity measurements 
4.1.1 Direct binding of rimonabant towards MOR in radioligand competition binding 
assays performed in wild type and CB1 K.O. mouse forebrain membranes 
The direct binding affinity of rimonabant towards MOR was analyzed in competition 
binding assays with the highly MOR selective tritiated peptide agonist DAMGO 
(3HDAMGO) using membranes prepared from wild type (w.t.) and CB1knock-out (CB1 
K.O.) mice forebrain. The competing ligands were unlabeled DAMGO (as a control) or 
rimonabant added in increasing concentrations. 
Our results demonstrate that rimonabant reduced 3HDAMGO specific binding both in 
wild type and CB1 K.O. mice only at the highest, micromolar concentrations (Fig. 9). Even at 
this concentration the reduction of MOR specific binding was very small, 20 % compared to 
total specific binding (=100 %). The binding capacity of rimonabant remained unaltered in 
CB1 K.O. mice forebrain membranes. As a result the IC50 values of rimonabant were in the 
micromolar range both wild type and CB1 K.O. mouse forebrain membranes (Fig. 9). For 
comparison the MOR specific DAMGO possessed a binding affinity in the nanomolar range 
as expected. Important to note that the affinity of DAMGO was not altered significantly when 
the CB1 receptor was not present in the forebrain membranes (Fig. 9). 
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Figure 9 Direct binding affinity measurements of rimonabant towards MOR in 
competition binding experiments in wild type and CB1 K.O. mouse forebrain 
membranes. The figures represent the specifically bound fixed concentrations of [3H]DAMGO in 
percentage in the presence of increasing (10-10-10-5 M) concentrations of unlabeled rimonabant and 
DAMGO (for control).  The calculated logIC50 (the measurement of ligand binding capacity) of 
unlabeled rimonabant and DAMGO are also indicated in column diagrams. Points and columns 
represent means ± S.E.M. for at least three experiments performed in duplicate. Total and non specific 
binding was settled as 100% and 0% respectively. The antilogarithm form of logIC50 (IC50) values are 
presented in brackets. For additional figure information see Fig. 8A.  
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4.1.2 Direct binding of rimonabant towards MOR and DOR in radioligand competition 
binding assays performed in CHO-rMOR or CHO-mDOR cell membranes 
To investigate the direct binding affinity of rimonabant towards MOR more thoroughly 
we performed our radioligand competition binding assays in membrane fractions of CHO 
cells overexpressing rat MOR (CHO-rMOR) to insure a better receptor-ligand interaction. In 
physiological conditions CHO cell lines express neither MORs nor CB1 receptors 
128,171
, that 
is why they are suitable for the overexpression of these receptors. At the same time we 
analyzed the binding properties of rimonabant towards DOR straightforwardly in CHO cell 
membranes overexpressing mouse DOR (CHO-mDOR). The presence of DOR specific 
binding in untransfected CHO cell lines will be discussed above. The equilibrium competition 
binding experiments were carried out again with [
3
H]DAMGO and with the DOR selective 
tritiated agonist Ile
5,6
deltorphin II ([
3
H]Ile
5,6
deltorphin II). Additionally radiolabeled opioid 
receptor specific antagonists were also applied, namely the tritiated opioid receptor specific 
naloxone ([
3
H]naloxone) and the DOR specific naltrindole ([
3
H]naltrindole).  
In parental (untransfected) CHO cell lines (pCHO) no significant displacement was 
observed between [
3
H]Ile
5,6
deltorphin II and unlabeled Ile
5,6
deltorphin II (Fig. 10), therefore 
the points could not be fitted with non-linear regression. Additionally similar 
[
3
H]Ile
5,6
deltorphin II binding values were detected in the presence of unlabeled 
Ile
5,6
deltorphin II and 10 μM naloxone (Fig. 10), which is applied for the calculation of non-
specific binding (see section ‎3.5.2). Thus the detected bound [3H]Ile5,6deltorphin II was due to 
non-specific binding, hence we can conclude that in CHO cell lines DORs are not expressed 
physiologically.  
According to our competition binding assays performed in CHO-rMOR, rimonabant 
reduced [
3
H]DAMGO total specific binding (100%) in the micromolar range (3x10
-7
- 10
-5 
M; 
Fig. 11A) and at the highest applied concentrations the reduction approximately reached the 
non-specific binding level (0%; Fig. 11A). As a result rimonabant bound to the MOR with a 
1.74 μM IC50 value (Fig. 11A). [
3
H]Ile
5,6
deltorphin II total specific binding was also inhibited 
only when rimonabant was present in micromolar concentrations, however at the highest 
concentrations the total specific binding of the radioligand was only inhibited approximately 
50% (Fig. 11B). Nevertheless the IC50 value of rimonabant again resulted in the micromolar 
range (2.8 μM) during DOR binding (Fig. 11B). 
Interestingly rimonabant showed a markedly different binding character when 
radiolabeled opioid receptor antagonists were applied in the assays: the total specific binding 
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of both tritiated opioid antagonists were firstly reduced when rimonabant was present in the 
nanomolar range (10
-10
-10
-9
 M), which was followed by a short plateau phase. Finally in the 
micromolar range the total specific binding of the opioid antagonists were again decreased to 
the similar level as seen in the case of the radioactive opioid agonists (Fig. 11A and B). The 
“two phase” inhibition suggests a higher and a lower affinity binding site on both MOR and 
DOR, which can be both occupied by rimonabant with a subnanomolar (high affinity binding 
site) and micromolar (low affinity binding site) IC50 value (Fig. 11A and B). Moreover 
rimonabant significantly inhibited MOR antagonist binding more effectively in the 
micromolar range compared to MOR agonist binding (1.74 μM vs. 0.18 μM; P < 0.01, 
unpaired t test, two-tailed P value; Fig. 11A).   
Thus in the micromolar range rimonabant can affect the ligand binding of MOR and 
DOR directly, moreover rimonabant can also inhibit specific antagonist binding in the 
nanomolar range with very high affinity. 
 
Figure 10 DOR specific ligand binding in pCHO cell membranes. Bound 
[3H]Ile5,6deltorphin II in counts per minute (cpm) in fixed concentrations in the presence of increasing 
(10-10-10-5 M) concentrations of unlabeled  Ile5,6deltorphin II and 10 μM naloxone in pCHO cell 
membranes. Points and columns represent means ± S.E.M. for at least three experiments performed in 
duplicate. For additional figure information see Fig. 8A. 
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Figure 11  Direct binding affinity measurements of rimonabant towards MOR and 
DOR in competition binding experiments in CHO-rMOR (A) and CHO-mDOR (B) 
membranes. The figure shows the percentage of specifically bound fixed concentrations of 
[3H]DAMGO/[3H]naloxone or [3H]Ile5,6deltorphin II/[3H]naltrindole in percentage in the presence of 
increasing (10-10-10-5 M) concentrations of unlabeled rimonabant in CHO-rMOR (A) or CHO-mDOR 
(B) membrane fractions. The calculated logIC50 (ligand binding capacity) of unlabeled rimonabant is 
also indicated. Points and columns represent means ± S.E.M. for at least three experiments performed 
in duplicate. The two columns close to each other indicate the logIC50 values of rimonabant for the 
high and low affinity binding sites. Total and non specific binding was settled as 100% and 0% 
respectively. The antilogarithm form of logIC50 (IC50) values are presented in brackets. * indicates the 
significant reduction of rimonabant logIC50 value in [
3H]naloxone displacement compared to 
[3H]DAMGO displacement (unpaired t-test, two-tailed P value). **: P <0.01. For additional figure 
information see Fig. 8A. 
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4.1.3 Docking experiments with rimonabant to inactive and active MOR homology 
model 
To underpin our competition binding assay results performed in CHO-rMOR cell lines, 
we carried out docking calculations. Docking, a particular field of molecular modeling is a 
widely used tool to simulate the preferred orientations of a ligand in the binding site. 
Rimonabant was docked to the homology models of the inactive and active state of the MOR. 
The MOR agonist DAMGO and the opioid antagonist naloxone were also docked to the 
receptor models for control. Because DAMGO contains an N-MePhe (N-
methylphenylalanine) in its sequence, there is a possibility that it adopts a cis Gly
3
-N-MePhe
4
 
peptide bond 
172
. According to this, DAMGO was docked both in all-trans form and with a cis 
Gly
3
-N-MePhe
4
 peptide bond (cis-DAMGO). Since the applied active and inactive MOR 
homology models already contained JOM-6 and nor-BNI, respectively, these ligands were 
also docked to the receptor models to cross validate our docking experiments. Each ligand 
was docked to both receptor conformations to compare their preference for the specific state 
of MOR. 
In the first calculation the receptors were rigid and the ligands were flexible except that 
the aliphatic rings of the ligands were kept in the conformation obtained by the energy 
minimization (Fig. 12A). As expected during our docking experiments JOM-6 and nor-BNI 
achieved the same docking poses as published previously 
161
. Even though rimonabant is a 
highly specific CB1 receptor antagonist, the ligand bound to the active state of MOR with 
surprisingly low docking energies (Fig. 12A). Moreover, rimonabant bound to the inactive 
state of MOR with a much lower docking energy, resulting a positive receptor activation 
energy unlike DAMGO, cis-DAMGO and JOM-6 (Fig. 12A). In fact the receptor activation 
energy of rimonabant was very similar to that of the antagonist naloxone (Fig. 12A). In the 
second calculation the possibility of applying flexible aliphatic rings during the experiments 
did not improve the docking energies in general (Fig. 12B).  
As an important difference between the binding modes, rimonabant docked to the 
inactive and active state of the receptor by the opposite ends (Fig. 13A and B). Also a 
hydrogen bond occurs between Thr218 (T218) in the TM7 domain and the hydrazide group of 
rimonabant (Fig. 13C) in the inactive state of the binding pocket, while no hydrogen bonds 
were observed in the binding pocket of the active receptor. 
Summarizing the results of our docking calculations, we observed that rimonabant binds 
to the active conformation of MOR with a surprisingly low energy similar to the agonist 
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DAMGO. However, the docking energies were even lower in the inactive state of the MOR 
suggesting that rimonabant has a preference for the inactive state of MOR. These findings 
raise the possibility that rimonabant acts as an antagonist on MOR. Nevertheless, only the 
inactive state gives the opportunity to form a hydrogen bond between rimonabant and one of 
the residues in the binding pocket. 
 
Figure 12  Docking energies and the calculated receptor activation energy of 
rimonabant compared to the indicated ligands in docking experiments accomplished 
with rigid receptor, rigid ring (A) and rigid receptor, flexible ring (B) in inactive and 
active MOR. The 3D coordinates of the inactive and active conformations of MOR, and the 
preparations of the ligands for docking are described under section ‎3.6. Receptor activation energy 
was calculated by subtracting the docking energy of the activated MOR from that of the inactive 
MOR. The data are represented in kcal/mol. 
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Figure 13  The docking pose of rimonabant in the inactive (A) and active (B) MOR, 
and the hydrogen bond between rimonabant and T218 (C). Rimonabant is indicated in 
yellow (the nitrogen and hydrogen atoms of the hydrazide group are shown in blue and white, 
respectively). The hydrogen bond is highlighted with a black dotted line; the hydrogen acceptor 
(oxygen) is shown in red on T218. The essential extracellular loops (ECL) and transmembrane regions 
(TM) are indicated on the inactive conformation of MOR for clarity. The docking poses were analyzed 
and visualized by the program Chimera. 
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4.2 MOR and DOR mediated G-protein activity measurements 
4.2.1 The effect of rimonabant on DOR G-protein basal activity in [35S]GTPγS binding 
assays, in CHO-mDOR and pCHO cell membranes 
Further on we examined whether the DOR mediated G-protein basal activity can be 
altered by rimonabant, that is whether it can exert its inverse agonistic effect on DOR. The 
experiments were accomplished in functional [
35S]GTPγS binding experiments, with a non-
hydrolysable radiolabeled GTP analog,
 
[
35S]GTPγS. The assays were performed in 
CHO-mDOR and pCHO cell membranes, to avoid interaction of DORs with other opioid and 
cannabinoid receptors, and also to see clearly the direct actions of rimonabant on DOR 
G-protein coupling.  
According to our results rimonabant significantly decreased the DORs basal activity 
(100%, Fig. 14A), with an efficacy (Emax) of 48.1% and with a potency (EC50) of 1.3 μM 
(Fig. 14A). Thus rimonabant may behave as an inverse agonist at DOR. 
To investigate whether the inverse agonistic effect of rimonabant on DOR is indeed 
DOR related, we measured the specifically bound [
35S]GTPγS when 10 μM rimonabant was 
incubated together with 1 μM of the DOR specific antagonist naltrindole, again in 
CHO-mDOR cell membranes (Fig. 14B). Our results pointed out that naltrindole failed to 
reverse the inverse agonistic effect of rimonabant (Fig. 14B), therefore DOR is not involved 
in this action. For comparison, naltrindole significantly inhibited DPDPE-stimulated 
[
35S]GTPγS binding (Fig. 14B). Also the MOR agonist morphine and the KOR agonist 
U50488, together with naltrindole failed to alter the G-protein basal activity of DOR 
significantly (Fig. 14B). This confirms the lack of both MOR and KOR in the CHO-mDOR 
cell membranes, and the pure antagonistic character of naltrindole. Additionally rimonabant 
also significantly decreased G-protein basal activity in pCHO cell membranes (Fig. 14C), 
which did not contain DORs (DPDPE did not alter basal activity, see Fig. 14C), which 
underpins the non-DOR related inverse agonistic effect of rimonabant. 
These results were in accordance with previous studies with CHO-MOR cell 
membranes in similar experimental conditions 
128,171
.  
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Figure 14  The effect of rimonabant on DOR G-protein basal activity in ligand-
modulated [
35S]GTPγS binding assays, in CHO-mDOR (A and B) and in pCHO (C) cell 
membranes. A and C represents the  specifically bound [35S]GTPγS in percentage in the presence of 
increasing concentrations (10-10-10-5 M) of rimonabant or DPDPE in CHO-mDOR (A) or pCHO cell 
membranes (C). The calculated Emax (G-protein maximal efficacy) and logEC50 (ligand potency) 
values are also presented in column diagrams. * denotes the significant alterations of DOR G-protein 
Emax value (unpaired t-test, two-tailed P value) compared to basal activity (100%) in the presence of 
rimonabant. In case of C the error bars are shorter than the points itself. B represents specifically 
bound [35S]GTPγS in percentage in the presence of 10 μM of the indicated ligands alone or together 
with 1 μM naltrindole in CHO-mDOR cell membranes. × indicates the significant alterations in 
specifically bound [35S]GTPγS (One-way ANOVA, Bonferroni’s Multiple Comparison post hoc test), 
compared to basal activity  in the presence of rimonabant or DPDPE. * indicates the significant 
reduction in the specifically bound [35S]GTPγS during DPDPE stimulation in the presence of NTI 
compared to DPDPE alone. Total (=basal activity) and non specific binding was settled as 100% and 
0% respectively. Points and columns represent means ± S.E.M. for at least three experiments 
performed in triplicate. ×××, ***: P <0.001; ×: P < 0.05. For additional figure information see Fig. 8B.  
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4.2.2 The effect of rimonabant on DOR G-protein activation in DPDPE-stimulated 
[
35S]GTPγS binding, in CHO-mDOR cell membranes 
In the next step we examined whether rimonabant at micromolar concentration range 
has any effect on DORs G-protein activation during receptor stimulation. The experiments 
were again accomplished in functional [
35S]GTPγS binding experiments using CHO-mDOR 
cell membranes. The receptor was stimulated with the enkephalin analogue DOR specific 
agonist DPDPE, which activated the DOR the most effectively compared to our other DOR 
activator ligand candidates (data not shown).   
 DPDPE stimulated the DOR with a potency (EC50) of 12.4 nM and the receptors 
G-protein had a maximal stimulation or efficacy (Emax) of 285.6 % during DPDPE stimulated 
receptor activation (Fig. 15). Rimonabant in 1 and 10 M concentrations significantly 
decreased the DORs G-protein efficacy (Fig. 15) and also the potency of DPDPE but only in 
10 µM concentrations (Fig. 15). 
 Thus rimonabant inhibited the DPDPE-induced maximal G-protein stimulation of the 
DOR and also the potency of the stimulator ligand in the micromolar range when no 
cannabinoid or other opioid receptors were present in the experimental system. 
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Figure 15 The effect of rimonabant on DOR G-protein activation in 
DPDPE-stimulated [
35S]GTPγS binding, in CHO-mDOR cell membranes. The figure 
represents the specifically bound [35S]GTPγS in percentage in the presence of increasing 
concentrations (10-10-10-5 M) of DPDPE in the absence or presence of the indicated rimonabant 
concentrations. The calculated Emax (G-protein maximal efficacy) value of DOR G-protein and logEC50 
(ligand potency) value of DPDPE are also indicated. Points and columns represent means ± S.E.M. for 
at least three experiments performed in triplicate. * indicates the significant reduction in Emax and 
logEC50 values in the presence of rimonabant compared to DPDPE alone (One-way ANOVA, 
Bonferroni’s Multiple Comparison post hoc test). The DOR basal activity level was settled as 100%. 
The antilogarithm form of logEC50 (EC50) values are presented in brackets. ***: P < 0.001; 
**: P < 0.01. For additional figure information see Fig. 8B. 
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4.2.3 The effect of rimonabant on MOR and DOR G-protein activation in 
agonist-stimulated [
35S]GTPγS binding, in wild type and CB1 and CB1/CB2 
receptor double knock-out mouse forebrain membranes 
To underpin our opioid receptor G-protein activation results, we accomplished the 
assays in mouse forebrain membranes. In this brain region both opioid and cannabinoid 
receptors are expressed in eligible amount 
114,173,174
. Therefore agonist stimulated MOR and 
DOR G-protein activity can be studied when the receptors are expressed in physiological 
conditions and when cannabinoid and other opioid receptors are present, thus interactions may 
occur between them. The investigations were also performed in CB1 and CB1/CB2 double 
knock-out mice (CB1 K.O. and CB1/CB2 K.O. respectively), because previously our group 
demonstrated an interaction between the CB2 receptor and MOR in mice forebrain 
113
. Since 
the inhibitory actions of rimonabant occurred from 1 μM in the cell membranes, we carried 
out our further experiments with this concentration.  
In wild type (w.t.) mouse forebrain membranes the maximal efficacy (Emax) of MOR 
during DAMGO-stimulation was significantly decreased in the presence of rimonabant 
together with the potency (EC50) of DAMGO (Fig. 16). In CB1

 knockout animals the 
maximal efficacy of MOR mediated G-protein was also significantly diminished by 
rimonabant (Fig. 16), whereas the potency of DAMGO remained unaltered (Fig. 16). The 
lack of both cannabinoid receptors did not modulate the inhibitory effect of rimonabant on 
MOR G-protein activity (Fig. 17A), thus we can rule out the role of CB1 and CB2 receptors in 
the observed effects of rimonabant upon MOR function. 
During DPDPE-stimulated DOR G-protein activation, the presence of rimonabant 
produced a significant attenuation in the maximal efficacy of DORs G-protein activity (Fig. 
17B) and in the potency of the stimulatory ligand (Fig. 17B) similar to that in the wild type 
mouse forebrain membranes. The reduced maximal efficacy of the receptor and the potency 
of the activating ligand - similar to that of MOR - were also established in the CB1/CB2 K.O. 
mouse forebrain when rimonabant was present (Fig. 17B).  
Further on we wanted to verify that the inhibitory actions of rimonabant are not due to 
the unspecific inverse agonistic effect discussed previously under section  4.2.1. To exclude 
this possibility we applied L-epinephrine, which is a non-selective endogenous adrenergic 
receptor agonist. With L-epinephrine we stimulated adrenergic receptors (AR) in [
35S]GTPγS 
binding assays performed in CB1/CB2 K.O. mouse forebrain membranes. ARs are highly 
expressed in the forebrain structures and can coupled to Gi/o type G-proteins such as the 2 
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type receptors 
175
, therefore they can be monitored by L-epinephrine-stimulated [
35S]GTPγS 
binding assays (see section ‎3.5.3). In addition there is evidence that 2 ARs are expressed 
physiologically in CHO cell lines (see web reference 
G
), also it has been previously reported 
that rimonabant is able to inhibit α2 adrenergic receptor binding in micromolar concentrations. 
Therefore the non-CB1 mediated inverse agonistic effect of rimonabant can be mediated 
through 2 ARs. 
L-epinephrine activated its specific receptor with 31.6 nM potency (Fig. 18) and the 
coupled G-protein had a 166.8% maximal efficacy during the activation (Fig. 18). In the 
presence of 10 M rimonabant neither of the parameters changed significantly (Emax: 162%; 
EC50: 26.7 nM; Fig. 18), thus the inhibitory actions of rimonabant are not due its non-specific 
inverse agonistic actions.  
To summarize the [
35S]GTPγS binding experiments performed in forebrain 
membranes, we can conclude that rimonabant in the micromolar range in vitro inhibits 
agonist-stimulated MOR and DOR G-protein efficacy and ligand potency. Thus the inhibitory 
actions of rimonabant cannot only occur when both receptors are overexpressed in cell lines, 
but also when they are expressed in physiological conditions. Further on in case of both 
opioid receptors the reduced G-protein efficacy together with the decreased DPDPE potency 
was independent from cannabinoid receptors. 
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Figure 16 The effect of rimonabant on MOR G-protein activation in 
DAMGO-stimulated [
35S]GTPγS binding, in wild type and  CB1 knock-out mouse 
forebrain membranes. The figure represents the specifically bound [35S]GTPγS in percentage in 
the presence of increasing concentrations (10-9-10-5 M) of DAMGO in the absence or presence of 1 
M rimonabant. The calculated Emax (maximal efficacy) value of MOR G-protein and logEC50 (ligand 
potency) value of DAMGO are also indicated in column diagrams. Points and columns represent 
means ± S.E.M. for at least three experiments performed in triplicate. * indicates the significant 
reduction in Emax and logEC50 values in the presence of rimonabant compared to DAMGO alone in 
wild type or in CB1 receptor knock-out mouse (unpaired t-test, two-tailed P value). The MOR 
basal activity level was settled as 100%. The antilogarithm form of logEC50 (EC50) values are 
presented in brackets. ***: P < 0.001; **: P < 0.01; *: P < 0.05. For additional figure information see 
Fig. 8B. 
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Figure 17 The effect of rimonabant on MOR and DOR G-protein activation in (A) 
DAMGO- and (B) DPDPE-stimulated  [
35S]GTPγS binding, in wild type and  CB1/CB2 
knock-out mouse forebrain membranes. The figure represents the specifically bound 
[35S]GTPγS in percentage in the presence of increasing concentrations (10-10-10-5 M) of DAMGO (A) 
or DPDPE (B) in the absence or presence of 1 M rimonabant. The calculated Emax (maximal efficacy) 
value of MOR (A) and DOR (B) G-protein and logEC50 (ligand potency) value of DAMGO (A) and 
DPDPE (B) are also indicated. Points and columns represent means ± S.E.M. for at least three 
experiments performed in triplicate. * indicates the significant reduction in Emax and logEC50 values in 
the presence of rimonabant compared to DAMGO or DPDPE alone in wild type or in CB1/CB2 
receptor double knock-out mouse (unpaired t-test, two-tailed P value). The receptor basal 
activity level was settled as 100%. The antilogarithm form of logEC50 (EC50) values are presented in 
brackets. ***: P < 0.001; **: P < 0.01; *: P < 0.05. For additional figure information see Fig. 8B. 
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Figure 18 The effect of rimonabant on AR G-protein activation in 
L-epinephrine-stimulated [
35S]GTPγS binding, in CB1/CB2 knock-out mouse forebrain 
membranes. The figure represents the specifically bound [35S]GTPγS in percentage in the presence 
of increasing concentrations (10-10-10-5 M) of L-epinephrine in the absence or presence of 10 M 
rimonabant. The calculated Emax (maximal efficacy) value of AR G-protein and logEC50 (ligand 
potency) value L-epinephrine are also indicated in column diagrams. Points and columns represent 
means ± S.E.M. for at least three experiments performed in triplicate. AR basal activity was settled as 
100%. The antilogarithm form of logEC50 (EC50) values are presented in brackets. AR: adrenergic 
receptor. For additional figure information see Fig. 8B. 
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5 DISCUSSION 
Rimonabant was the first CB1 receptor antagonist/inverse agonist to be developed, and 
it is still a perfect tool for antagonizing CB1 related effects (for review see 
123
). Later it turned 
out that rimonabant had several non-cannabinoid related effects such as decreasing alcohol 
intake, opiate self-administration and increasing smoking cessation (for review see 
135
). There 
is also evidence that rimonabant can interact with several GPCRs and ion channels (for 
review see 
134
). 
This study focuses on the interaction between rimonabant and the MOR and DOR. 
The interaction was studied at ligand-receptor level in competition binding experiments and 
docking experiments, and at the receptor-G-protein level in functional [
35S]GTPγS binding 
assays. 
In our competition binding experiments performed with mouse forebrain membranes 
rimonabant could only displace [
3
H]DAMGO in the highest concentrations, and even at that 
level it could only cause a minor decrease in the specific binding of the radiolabeled MOR 
agonist. The lack of CB1 receptor did not affect the binding characteristics of either ligand, as 
we got comparable results in CB1 knockouts as well. We also carried out equilibrium 
competition binding experiments in CHO-rMOR cell membranes to measure the ligand-
receptor interaction more precisely. [
3
H]DAMGO was fully displaced from its receptor in 
CHO-rMOR cell membranes by rimonabant, but only in higher concentrations, which resulted 
a similar micromolar affinity for the compound. Other publications also reported micromolar 
affinity for rimonabant on MOR in similar experimental conditions 
128,141,142
. On the other 
hand rimonabant was able to displace [
3
H]naloxone with a significantly lower logIC50 value 
compared to [
3
H]DAMGO. In CHO-mDOR cell membranes rimonabant decreased only 50% 
of both the DOR agonist [
3
H]Ile
5,6
deltorphin II and the DOR antagonist [
3
H]naltrindole total 
specific binding. For comparison in Kathmann and co-workers study rimonabant inhibited 
[
3
H]naltrindole  binding by only 20% 
142
, which can be partly explained by the different 
experimental conditions applied during the assay (incubation time and temperature, final 
volume etc.) and by the applied cell lines. Additionally in case of both DOR specific 
radioligands rimonabant reached an IC50 value in the micromolar range, similar to our 
competition binding experiments performed in CHO-rMOR cell membranes. As reported in 
previous studies rimonabant also bound with an IC50 in the micromolar range to other 
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members of the GPCR family, such as adrenergic and 5-HT6 receptors or to ion channels, like 
calcium, sodium and potassium channels (for review see 
134
). 
Interestingly a higher affinity binding site for rimonabant was measured in the 
displacement of both [
3
H]naloxone and [
3
H]naltrindole:  rimonabant also displaced the 
antagonist [
3
H]naloxone and [
3
H]naltrindole in the subnanomolar range with a very high 
affinity, which did not occur during the displacement of the agonist [
3
H]Ile
5,6
deltorphin II and 
[
3
H]DAMGO. The high and low affinity binding sites are common in GPCRs 
176
, and 
previously our group had demonstrated it on opioid receptors, including on the MOR 
177
. It is 
known that antagonists stabilize the receptors in the inactive state, thus they prefer the 
inactive receptor form, while agonists prefer the active receptor state, since they stabilize the 
active form 
4,18
 (see section ‎1.1.3). Accordingly in our competition binding experiments 
rimonabant may behave as an antagonist, since it displaced the radioactive opioid receptor 
antagonists (which probably maintains the MOR or DOR to the inactive state) from the higher 
affinity binding site, which did not occur during the displacement of the radiolabeled opioid 
agonist (which probably stabilized the MOR or DOR in the active state). 
Further on we investigated the binding capabilities of rimonabant towards the MOR in 
in silico docking calculations. Docking calculations gives the opportunity to gather 
information about the receptor-ligand complex, such as the estimate of binding energy, the 
possible intermolecular interactions, orientations or the occurring energy alterations, which 
are hard to achieve in in vitro studies. According to our calculations rimonabant 
accommodated to both receptor conformations with a low docking energy (which was 
unexpectedly low in the case of the active state), but with a high energy expense for the 
activated receptor compared to the inactive one, suggesting an antagonistic character for the 
ligand. This is supported by our finding that only the inactive state gives the possibility for a 
hydrogen bond between rimonabant and a residue in the binding pocket of MOR. As for the 
docking calculations for the DOR, it is under progress. 
It is well known that G-proteins have a constitutive activity (for review see 
178
) which 
can be further modified upon ligand binding (see section ‎1.1.3).  In turn the altered basal 
activity initiates different types of signaling cascades 
40
. For further investigations we 
examined the impact of rimonabant on the basal activity of the DORs G-protein, which can 
give us valuable information about the binding character of rimonabant on DOR. MOR was 
investigated in this aspect with similar methods previously by Cinar and Szűcs 128 and later 
Seely and co-workers 
171
. According to their studies rimonabant decreased G-protein basal 
activity in CHO-MOR cells, however in both cases the effect was not MOR specific, since it 
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was not reversed by naloxone and it also occurred in untransfected cell lines.  In our 
[
35S]GTPγS binding assays the inverse agonistic effect of rimonabant was unrelated to DOR, 
and also confirmed the non-CB1 mediated inverse agonistic effect. Therefore the agonistic 
(since rimonabant did not enhance DOR G-protein basal activity) and inverse agonistic 
character of rimonabant at DOR can be excluded as it is pertained to the MOR. As regard to 
the non-CB1 related inverse agonistic effect of rimonabant, it has been proven to be pertussis 
toxin sensitive and it was demonstrated in different types of brain tissues in several other 
publications so far 
126,128–130
. 
Since rimonabant affected the MORs and DORs ligand binding, it raises the 
possibility that it can also interfere with the receptors G-protein activation during MOR and 
DOR specific agonist stimulation. In case of DOR the investigations initiated again in CHO-
mDOR cell lines. The MOR was previously studied in CHO cell lines overexpressed with 
MOR in similar experimental conditions again by Cinar and Szűcs 128 and afterwards by Seely 
et al 
171
. MOR DAMGO-induced maximal stimulation was slightly, but not significantly 
reduced in the presence of 10 M rimonabant 128 and also the potency of the agonist morphine 
stimulatory ligand was decreased in the presence of the same rimonabant concentration 
171
. 
These findings indicate an antagonistic behaviour for rimonabant on MOR 
171
. In our 
DPDPE-induced DOR G-protein activity measurements, rimonabant inhibited the maximal 
stimulation of the DORs G-protein and also the potency of the stimulator ligand significantly. 
Moreover the inhibition occurred in the micromolar concentration range, similarly as in direct 
affinity measurements in CHO-mDOR cell membranes and as in the previously reported 
MOR G-protein activity results. 
The CHO cell line with homogeneous population of overexpressed MOR or DOR is a 
useful tool to investigate the direct interaction between rimonabant and these two opioid 
receptors, since there is no cannabinoid or other opioid receptors in the system which can 
interact with them, thus the direct effect of rimonabant can be measured more accurately. 
However as it was discussed under section ‎1.1.5, in physiological conditions GPCR receptors 
often communicate with each other via overlapping signaling pathways or more even via 
heterodimerization 
29,35,38,41
, which in addition alters there functionality 
37,41
. Taking this into 
consideration we investigated the impact of rimonabant on MOR and DOR G-protein 
activation in mouse forebrain, where the cannabinoid and opioid receptors are expressed in 
adequate quantity 
74,75,114,179
. According to our results, in 1 M concentrations the attenuated 
efficacy of MOR and DOR G-protein and the reduced potency of the stimulatory ligands also 
occurred in the presence of rimonabant, when the receptors were expressed in physiological 
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conditions. Moreover the decreased maximal MOR G-protein efficacy was also observed 
when the CB1 receptors were not expressed in the forebrain; therefore it is a CB1 receptor 
independent action, at least in the forebrain region. In previous MOR G-protein studies ten 
times higher concentrations of rimonabant significantly altered the potency of DAMGO CB1 
receptor independently, but did not change the maximal stimulation over basal activity of the 
MOR 
128
. 
Despite that CB2 is mostly present in non-neuronal peripheral tissues, increasing 
amount of data shows its neuronal and non-neuronal presence in the CNS 
180,181
. Previously 
our group also showed a CB2 mediated noladin ether influence on forebrain MOR G-protein 
activation 
113
 as well as an inhibitory role of a CB2 antagonist (SR144528) at MOR activity in 
brainstem 
112
. To examine whether the CB2 receptor has a role (if any) in the observed 
changes in MOR G-protein stimulation, in the next step we performed the 
DAMGO-stimulated [
35S]GTPγS binding experiments on CB1/CB2 double knockout mice 
forebrain. According to our data, particularly that rimonabant decreased MOR signaling in the 
same extent in double knockouts as in controls, the role of the CB2 can also be excluded. 
These results were however expected since rimonabant has a very poor affinity for the CB2 
receptor 
62
. Additionally the significantly reduced DOR G-protein maximal efficacy and 
DPDPE potency was also unaltered when neither cannabinoid receptors were present in the 
forebrain. Thus our [
35S]GTPγS binding experiments conducted in mouse forebrain 
membranes highlighted a cannabinoid receptor independent MOR and DOR function. 
To make certain that the observed actions of rimonabant are not due to the non-CB1 
related inverse agonistic effect, we examined L-epinephrine-induced G-protein activity in the 
presence of rimonabant in CB1/CB2 receptor double knock-out mouse forebrain membranes. 
The α2 AR is known to be expressed physiologically in CHO cell lines and it is present in high 
levels in certain forebrain regions, in addition there is evidence that rimonabant can bind to 
this type of AR with micromolar affinity. According to our results rimonabant did not have 
any effect on adrenergic receptor G-protein maximal activity or L-epinephrine potency during 
L-epinephrine stimulation even at a very high, 10 μM concentrations. Therefore it strengthens 
our findings that the decreased agonist mediated MOR and DOR G-protein activation by 
rimonabant is an antagonistic mechanism and henceforth excludes the unspecific inverse 
agonistic effect. 
Thus according to our binding studies rimonabant can directly inhibit MOR and DOR 
specific agonist binding in micromolar concentrations and antagonist binding in 
subnanomolar concentrations independently from other opioid or cannabinoid receptors. Our 
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G-protein activity measurements also pointed out that rimonabant in micromolar 
concentrations can also inhibit agonist-stimulated MOR and DOR G-protein efficacy and 
potency again separately from other opioid and cannabinoid receptors. The mechanism behind 
these actions are possibly due to the antagonistic character of rimonabant towards the MOR 
and DOR, which possibility is confirmed by our results, together with other previous reports 
in many levels: (1) the reduced specific binding of the MOR and DOR antagonist in the 
subnanomolar concentration range, (2) rimonabant favored the inactive MOR receptor 
conformation, (3)  rimonabant on its own did not enhanced the basal activity of either of the 
investigated opioid receptors, therefore it did not behave as an agonist towards them, (4) the 
inverse agonistic character can also be excluded since it was neither a MOR nor DOR specific 
action, (5) the reduced potency of the stimulator ligand in our and other reported results and 
(6) the reduced Emax value of the MOR and DOR G-protein during agonist stimulation. 
Further on the allosteric effect can also be excluded since Kathmann and co-workers 
demonstrated previously that rimonabant did not show any allosteric properties on either 
MOR or DOR in dissociation kinetic studies 
142
. Although our results rules out the possibility 
of rimonabant exerting its observed effects through cannabinoid receptors, opioid receptors 
(apart from MOR or DOR) or even adrenergic receptors; other direct or indirect interactions 
might occur between MOR or DOR and other GPCRs. However this possibility is shadowed 
by the fact that rimonabant reduced MOR and DOR specific binding and G-protein function 
in similar concentrations. The direct antagonistic behaviour of rimonabant on MOR was also 
confirmed by Seely and co-workers with non-receptor assay methods 
171
: rimonabant blocked 
morphine attenuated intracellular cAMP levels in intact CHO cells overexpressed with human 
MOR and also reduced morphine analgesia in mouse tail-flick tests. 
After chronic rimonabant treatment the plasma protein level of the compound in 
humans is reported to be in the mid nanomolar range 
128,142,182
, which is ten times lower than 
the inhibitory concentration range of rimonabant observed in MOR and DOR agonist binding 
and agonist stimulated G-protein activation. However there is no data referring to the 
bioavailability of rimonabant or the tissue distribution during chronic treatment. Additionally 
rimonabant is a highly hydrophobic molecule, thus it can deposit in the fat tissue and easily 
penetrate through the BBB 
121
, also it has a long half-life (6-9 days with normal BMI and 16 
days with higher than 30 kg/m
2
, see web reference 
H
), because of its high plasma protein 
binding, which is almost 100% (see web reference 
H
). Therefore it is possible that rimonabant 
may reach micromolar concentrations in peripheral tissues or even in the brain during chronic 
treatment. Being aware of these informations the inhibitory actions of rimonabant on MOR 
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and DOR function observed in the micromolar range might have pharmacological relevance. 
If so the antagonistic behavior of rimonabant on DOR could partially explain the psychiatric 
side effects of the compound during chronic treatments, since DOR antagonists are proved to 
cause anxiogenic and depressive-like behaviour 
183,184
. It is worth to note that the mediatory 
role of KOR in the mood related side effects of rimonabant has been demonstrated previously 
144
. On the other hand the very low, subnanomolar inhibitory concentration range of 
rimonabant during MOR and DOR antagonists specific binding can also have 
pharmacological relevance, however these binding sites were exiguous in case of both 
receptors (about 20% of the total binding site population) and did not affect either of the 
receptors G-protein activity during agonist stimulation at this concentration level. 
Due to the limited footage of the thesis, it is only focusing on in vitro and in silico 
studies. However by the part of this study agonist stimulated MOR G-protein activity 
measurements were also performed after acute, low dose i.p. rimonabant treatment in mice 
forebrains. Similarly to the in vitro studies the compound inhibited maximal MOR G-protein 
efficacy independently from CB1 receptors 
152
, albeit the exact mechanisms and interactions 
involved in the effects of our in vivo data are more difficult to interpret. The KOR is also part 
of this overall study, however data are not yet published, but the manuscript is very close to 
submission. According to these data rimonabant also behaves as an antagonist towards the 
KOR. In addition administering the compound acutely, i.p., in low dose also reduced the KOR 
maximal G-protein activity and KOR protein expression rate CB1 receptor independently in 
mice forebrains. The low dose treatment reduced anxiety-like behaviour in mice as well. 
This overall study does not question the true high affinity of rimonabant towards the 
CB1 receptor; it is still a perfect tool to antagonize CB1 mediated effects (for review see 
123
), 
which was the original purpose of the compounds development 
62
. This study aimed to clarify 
the possible direct mechanisms between rimonabant and the opioid receptors, which had a 
growing number of literatures in the past few years. We think that the results reported in this 
thesis together with other published and yet unpublished data regarding to this overall study 
elucidates that rimonabant, although in relatively high concentrations, but can directly target 
opioid receptors.   
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6 SUMMARY 
 Rimonabant inhibited MOR and DOR specific agonist binding in micromolar 
concentrations and MOR and DOR specific antagonist binding in micro- and 
subnanomolar concentrations. In both cases the inhibition was independent from 
cannabinoid receptors and other opioid receptors. 
 Docking computational studies showed a favorable binding position of rimonabant to the 
inactive conformational state of MOR, combined with a possibility of a hydrogen bond 
between rimonabant and a residue in the inactive binding pocket of MOR. 
 In G-protein activity measurements we demonstrated that rimonabant has an inverse 
agonistic action independent from DOR, which confirms the non-CB1 related inverse 
agonistic effect of rimonabant. 
 During DOR agonist stimulation rimonabant inhibited DOR G-protein activity and DOR 
agonist potency in micromolar concentrations in membranes of CHO cell lines 
transfected with DOR. 
 Micromolar concentrations of rimonabant also inhibited MOR and DOR mediated 
G-protein activity and DOR agonist potency in mouse forebrain membranes 
independently from both cannabinoid receptors in agonist stimulated G-protein activity 
measurements. 
 Our results pointed out an antagonistic binding character for rimonabant towards MOR 
and DOR, which finding is also confirmed by subsequent reports. 
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7 CONCLUDING REMARKS 
We can certainly claim that rimonabant had a huge impact on cannabinoid receptor 
research as well as on the pharmaceutical industry. For the first time rimonabant gave the 
researchers the possibility to selectively antagonize the effects of CB1 receptors, however this 
ability was later shadowed by its inverse agonistic and unspecific actions (for review see 
123,134). 
 Taranabant 
185
, a highly selective CB1 receptor inverse agonist was also a clinical 
candidate for the treatment of obesity, with a more safer pharmacological profile compared to 
rimonabant
 141
. However the trials were stopped because it had also produced strong 
psychiatric side-effects 
186
. The rimonabant analogue AM251 
187
 has also been proven being 
involved in MOR related effects 
188,189
, moreover it was described as an antagonist for MOR 
171
. Thus examining the currently available CB1 receptor antagonists/inverse agonists, it is 
unlikely that the opioid receptors are their possible therapeutic targets. Partly because of their 
relatively low affinity towards these receptors and partly because the psychiatric side effects 
of these compounds are possibly mediated through these receptors 
144
. Reducing the BBB 
penetration of these compounds is a possible way to reduce their undesired psychiatric side 
effects and they are already under development (for review see 
190
). At the same time it can 
possibly make the CB1 receptors again a promising target for anti-obesity agents. As described 
in section ‎1.3.3 low dose combined treatment with opioid antagonists have promising 
therapeutic applications, partly due to the applied lower concentrations, which lowers the risk 
of possible side effects. Other interesting approaches are the construction of MOR agonist and 
CB1 receptor antagonist bivalent ligands, which than can target both receptors at the same 
time. For instance according to the study of Le Naour and co-workers the morphine and 
rimonabant bivalent ligand had potent analgesic effect and at the same time it was devoid of 
tolerance 
191
. Very recently hybrid molecules derived from fentanyl (a highly MOR selective 
agonist 
192
) and rimonabant has been developed and showed antagonist behaviour towards 
MOR and CB1 receptor both in vivo and in vitro 
193
. Thus combining opioid and cannabinoid 
ligands either in a monovalent or a bivalent form can be a possible approach for future 
therapeutic applications. 
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Rimonabant: egy CB1 receptor antagonista, 
mely direkt kölcsönhatásba lép a μ- és δ-opioid receptorral 
Ph.D. értekezés összefoglalója  
BEVEZETÉS 
Opioid és kannabinoid receptorok és interakciójuk  
A kannabinoid receptoroknak (CB1 és CB2) és a klasszikus opioid receptoroknak 
(µ-, - és -opioid receptorok; sorrendben MOR, KOR, DOR) számos közös jellemzőjük van: 
a G-fehérje kapcsolt receptor családhoz tartoznak (GPCR), az esetek többségében az ún. Gi/o 
típusú G-fehérjéhez kapcsolódnak és preszinaptikusan gátolják a különböző 
neurotranszmitterek felszabadulását. Bizonyos előagyi régiókban az opioid és CB1 receptorok 
nemcsak együtt lokalizálódnak, hanem együtt is expresszálódnak akár ugyanazon idegsejten 
is. Az is bebizonyosodott, hogy képesek indirekt vagy direkt módon egymás működését 
szabályozni, sőt heterodimert formálni. Ezen interakciók számos átfedő élettani funkciót 
eredményezhetnek, mint például a fájdalom, a hangulat, az energiaháztartás, a táplálkozás és a 
bélrendszer működésének szabályozása vagy az alkohol hatásainak közvetítése. 
A rimonabant és kapcsolata az opioid rendszerrel 
A rimonabant volt az első CB1 receptorra kifejlesztett szelektív antagonista, amely 
hatékony étvágycsökkentő hatása miatt kereskedelmi forgalomba is került. Azonban 2 évvel a 
bevezetését követően visszavonták a forgalmazását a krónikus szedés esetén fellépő erős 
pszichiátriai mellékhatásai, például súlyos depresszió, szorongás és öngyilkosság gondolata 
miatt. A rimonabant engedélyezése előtt illetve azt követően számos közlemény rávilágított a 
gyógyszer nem CB1-receptor-specifikus hatásaira. Ezek a hatások magas koncentráció 
alkalmazásakor voltak megfigyelhetők, és a rimonabant később leírt inverz agonista hatásával 
is magyarázhatók voltak. 
Egyre több adat van arra vonatkozóan, hogy a rimonabant képes módosítani az opioid 
rendszer működését. Bebizonyosodott, hogy a rimonabant által közvetített metabolikus 
hatásokat és kedélyállapot változásokat az opioid rendszer is képes befolyásolni. Ismert az is, 
hogy a rimonabant mindhárom klasszikus opioid receptorhoz kötődik relatíve nagy, 
mikromoláris koncentrációban. 
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CÉLKITŰZÉSEK 
A rimonabant, engedélyezett étvágycsökkentő gyógyszerként bekövetkezett, kudarcát 
részben a nem specifikus hatásai okozták, részben pedig az, hogy képes a vér-agy-gáton 
áthatolni. Ma már ismert, hogy a rimonabant nem CB1 receptor által közvetített hatásai az 
opioid rendszerre is kiterjednek. Azonban a tanulmányok többsége a rimonabant opioid 
rendszerre gyakorolt hatását leginkább CB1 receptor által közvetített hatásként írja le és csak 
kevés irodalmi adat van a rimonabant opioid receptorokra gyakorolt direkt hatására 
vonatkozóan. Nem ismert például, hogy a rimonabant milyen hatásmechanizmussal kötődik 
az opioid receptorokhoz (agonista, vagy antagonista karakterű), illetve az opioid receptorok 
által közvetített G-fehérje aktivációról is csak kevés információ áll rendelkezésre. Munkánk 
során ezért ezen direkt hatást vizsgáltuk meg részletesen a MOR-ra és DOR-ra fókuszálva. A 
MOR-ra azért esett a választás, mert a legintenzívebben kutatott opioid receptor típus, a DOR 
pedig - hozzá képest - általánosságban kevésbé tanulmányozott, ugyanakkor számos adat 
demonstrálja, hogy ígéretes terápiás célpont lehet. Kísérleteinkben a ligand-receptor és a 
receptor-G-fehérje kölcsönhatása szintjén vizsgáltuk:  
 A CB1 receptor szerepét a rimonabant a MOR-hoz való kötődésében 
 A rimonabant kötési tulajdonságait MOR-hoz és DOR-hoz, MOR-t és DOR-t 
túlexpresszáló kínai hörcsög ovárium sejteken (Chinese hamster ovary; CHO)   
 A rimonabant dokkolását a MOR aktív és inaktív homológ modelljeihez  
 A rimonabant hatását a DOR bazális aktivitására 
 A rimonabant hatását a MOR és a DOR által közvetített G-fehérje aktivációra agonista 
stimuláció során 
 A kannabinoid receptorok lehetséges szerepét ezen hatásokban  
A direkt affinitási vizsgálatokat kompetíciós kötési tesztekkel végeztük, opioid receptor 
specifikus radioligandok segítségével, míg a MOR és DOR közvetített G-fehérje aktivációs 
méréseket funkcionális [35S]GTPγS kötési tesztekkel vizsgáltuk.  
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MÓDSZEREK 
Radioligand kompetíciós kötési tesztek 
A radioligand kompetíciós kötési tesztek során állandó koncentrációjú radioaktívan 
jelölt szelektív MOR vagy DOR ligandok specifikus kötéseinek változását vizsgáltuk 
növekvő koncentrációjú jelöletlen rimonabant jelenlétében. A kapott radioligandok specifikus 
kötési értékeit kiértékelve görbeillesztő program segítségével, közvetve információt 
kaphatunk a jelöletlen ligand affinitásáról. 
Funckcionális [35S]GTPγS kötési teszt 
A G-fehérje aktivációs kísérletek során a Gαi/o GDP/GTP kicserélődését monitorozzuk 
egy radioaktívan jelölt, nem hidrolizáló [35S]GTPγS GTP analóggal. Ha növekvő 
koncentrációban aktiváljuk a receptort egy adott liganddal, akkor a specifikusan kötött 
[
35S]GTPγS mennyisége információt ad a vizsgált receptor által közvetített G-fehérje 
maximális aktivitásáról és a receptort aktiváló ligand potenciáljáról. Továbbá megállapítható a 
receptorhoz kötő ligand agonista, vagy antagonista karaktere is. 
Dokkolási kísérletek 
A dokkolási kísérletek lehetőséget adnak arra, hogy a ligand-receptor komplexről 
atomi szintű információkat gyűjtsünk, mint például a molekulák között lehetséges 
kölcsönhatások, orientációk, valamint dokkolási energiák, melyekről az általunk végzett in 
vitro kísérletek nem adnak választ. 
EREDMÉNYEK ÖSSZEFOGLALÁSA  
A ligand-receptor kölcsönhatás szintjén végzett kísérletek: 
 A rimonabant CB1 receptortól függetlenül gátolta a MOR agonista ligand kötődését 
mikromoláris koncentrációban, egér előagyban. 
 A rimonabant MOR-ral és DOR-ral transzfektált sejtvonal membránpreparátumon is 
gátolta a MOR és DOR specifikus agonista ligandok kötődését mikromoláris 
koncentrációban, míg a MOR és DOR antagonista ligandok specifikus kötődését nem 
csak mikromoláris hanem szubnanomoláris koncentrációkban is csökkentette. A gátló 
hatás mindkét esetben kannabinoid receptoroktól függetlenül ment végbe, mivel a 
CHO sejtekben fiziológiás körülmények között CB1 és CB2 receptorok nem 
expresszálódnak. 
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 A dokkolási kísérletek eredményei alapján a rimonabant az inaktív, tehát az 
antagonisták által stabilizált MOR konformációt preferálta. Az eredményt a 
rimonabant és a MOR inaktív kötőzsebének egyik aminosava közötti hidrogén kötés 
kialakulásának lehetősége is megerősíti.  
Receptor-G-fehérje kölcsönhatás szintjén végzett kísérletek: 
 A rimonabant önmagában inverz agonista hatást mutatott, azonban ez a DOR-t nem 
expresszáló vad típusú CHO sejtvonalon is érvényesült, így ez nem tekinthető DOR 
közvetített hatásnak.  
 A DOR-ral transzfektált CHO sejtvonalon végzett kísérletek alapján a DOR aktiválása 
során a rimonabant mikromoláris koncentrációban gátolta a receptor közvetített 
G-fehérje aktivitását és az aktiváló ligand potenciálját. 
 A rimonabant MOR és DOR stimulációja során egér előagyban is gátolta a MOR és a 
DOR által közvetített G-fehérje aktivitást, valamint csökkentette a DOR agonista 
ligand potenciálját is mindkét kannabinoid receptortól függetlenül, mikromoláris 
koncentrációban. 
KONKLÚZIÓ 
A CB1 receptor antagonista rimonabant direkt módon, kannabinoid receptoroktól 
függetlenül gátolja a MOR és DOR működését mikromoláris koncentrációban. Eredményeink 
alapján arra következtethetünk, hogy a gátló hatás antagonista jellegű, melyet a más 
kutatócsoportok által közölt eredmények is alátámasztanak.  
A viszonylag magas effektív koncentráció miatt kérdés, hogy a MOR és DOR terápiás 
célpontok lehetnek-e a rimonabant számára? A kompetíciós kötési tesztek alapján a 
rimonabant ugyan rendkívül alacsony koncentrációban gátolta az antagonista ligandok 
kötődését, de ez a gátlás meglehetősen kismértékű volt és a G-fehérje aktivációs vizsgálatok 
során már nem volt megfigyelhető ugyanabban a koncentráció tartományban. Ígéretes 
eredményeket mutat azonban a rimonabant-opioid hibrid ligandok fejlesztése, mely rendkívül 
új terület fejlődéséhez véleményünk szerint az itt demonstrált eredmények is 
hozzájárulhatnak. 
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Increasing number of publications shows that cannabinoid receptor 1 (CB1) speciﬁc compounds might act
in a CB1 independent manner, including rimonabant, a potent CB1 receptor antagonist. Opioids, cannab-
inoids and their receptors are well known for their overlapping pharmacological properties. We have pre-
viously reported a prominent decrease in l-opioid receptor (MOR) activity when animals were acutely
treated with the putative endocannabinoid noladin ether (NE). In this study, we clariﬁed whether the
decreased MOR activation caused by NE could be reversed by rimonabant in CB1 receptor deﬁcient mice.
In functional [35S]GTPcS binding assays, we have elucidated that 0.1 mg/kg of intraperitoneal (i.p.) rimo-
nabant treatment prior to that of NE treatment caused further attenuation on the maximal stimulation of
Tyr-D-Ala-Gly-(NMe)Phe-Gly-ol (DAMGO), which is a highly speciﬁc MOR agonist. Similar inhibitory
effects were observed when rimonabant was injected i.p. alone and when it was directly applied to fore-
brain membranes. These ﬁndings are cannabinoid receptor independent as rimonabant caused inhibition
in both CB1 single knockout and CB1/CB2 double knockout mice. In radioligand competition binding
assays we highlighted that rimonabant fails to displace effectively [3H]DAMGO from MOR in low concen-
trations and is highly unspeciﬁc on the receptor at high concentrations in CB1 knockout forebrain and in
their wild-type controls. Surprisingly, docking computational studies showed a favorable binding posi-
tion of rimonabant to the inactive conformational state of MOR, indicating that rimonabant might behave
as an antagonist at MOR. These ﬁndings were conﬁrmed by radioligand competition binding assays in
Chinese hamster ovary cells stably transfected with MOR, where a higher afﬁnity binding site was mea-
sured in the displacement of the tritiated opioid receptor antagonist naloxone. However, based on our
in vivo data we suggest that other, yet unidentiﬁed mechanisms are additionally involved in the observed
effects.
 2012 Elsevier Ltd. All rights reserved.
1. Introduction
Cannabinoids mediate their effects via activating at least two
types of cannabinoid receptors, CB1 and CB2 both G protein-
coupled (for review, see Howlett, 1998). CB1 cannabinoid receptor
is the most abundant G-protein coupled receptor (GPCR) type in
the brain with 10 times higher expression levels than other GPCRs.
In the central nervous system, the distribution of CB1 receptors
greatly varies between different parts of the brain and in different
neuronal cell types. They are widely expressed in several forebrain
regions including the olfactory bulbs (Herkenham et al., 1991), all
regions of the cerebral neocortex (Egertová and Elphick, 2000;
Glass et al., 1997; Herkenham et al., 1991; Matsuda et al., 1990),
the hippocampal formations (Herkenham et al., 1991; Jansen
et al., 1992), the subcortical regions (Breivogel et al., 1997; Herken-
ham et al., 1991; Julian et al., 2003; Matsuda et al., 1990; Robbe
et al., 2001), among others. CB2 receptors are predominantly
expressed in immune and hematopoietic cells. However, there
are many recent publications showing that CB2 receptors are also
present in some central and peripheral neurons (Beltramo et al.,
2006; Ross et al., 2001; Skaper et al., 1996; Van Sickle et al.,
2005), however, the role of the neuronal CB2 receptors has still to
be established.
Rimonabant, which was the ﬁrst selective and orally active CB1
antagonist (Rinaldi-Carmona et al., 1994), together with many
other CB1 and CB2 antagonists behave as an inverse agonist rather
than as a neutral antagonist (for review see Pertwee, 2005)
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indicating that CB1 and CB2 receptors can exist in a constitutively
active stage. It was the ﬁrst CB1 antagonist to be approved for
the treatment of obesity (Padwal and Majumdar, 2007), but was
withdrawn from the market in 2008 as it was found to cause strong
psychiatric disorders. Before, as well as after entering rimonabant
to the market there were several publications indicating its non-
CB1 receptor related actions (Breivogel et al., 2001; Hough et al.,
2009) and its dose related side effects (Beyer et al., 2010; Christen-
sen et al., 2007; Mitchell and Morris, 2007), suggesting rather
unspeciﬁc behavior at higher concentrations (reviewed in Raffa
and Ward, 2011).
It is well known that cannabinoid receptor system shares sev-
eral features with the l-opioid receptor (MOR) system. Both recep-
tor types are GPCR, mainly coupled to the inhibitory Gi/o proteins
(Burford et al., 2000; Demuth and Molleman, 2006). At this level
they might even functionally interact (Canals and Milligan, 2008;
Rios et al., 2006). The expression patterns of CB1 and MOR overlaps
in several parts of the CNS. In certain forebrain regions, such as
caudate putamen, dorsal hippocampus, substantia nigra and nu-
cleus accumbens, the MOR and CB1 receptors are not only co-local-
ized, but also co-expressed in the same neurons (Pickel et al., 2004;
Rodriguez et al., 2001; Salio et al., 2001). It has also been shown
that these two receptor subtypes can be cross-regulated (Schoffel-
meer et al., 2006) via a direct (Rios et al., 2006) or indirect interac-
tions (Hur and Kim, 2002). When studied in behavioral aspects
rimonabant reduced opiate self-administration and reward (Braida
et al., 2001; Fattore et al., 2005; Navarro et al., 2001) and suppress
morphine-induced feeding (Verty et al., 2003).
Previously we have shown that the putative endocannabinoid
noladin ether (NE; Hanus et al., 2001) is capable of attenuating
the functional activity of MOR in mouse forebrain and this effect
can be partially reversed by a CB2 antagonist (Páldyová et al.,
2008). Now we clariﬁed whether the decreased MOR activity
caused by NE, which is rather acting at CB1 receptors than at CB2,
could be reversed by rimonabant as well as we addressed to inves-
tigate the effect of rimonabant on the MOR G protein-activation
alone, without NE. Recently, it is believed that rimonabant applied
at high concentrations acts on a CB1 receptor independent manner
involving MORs (Cinar and Szücs, 2009), among others (Begg et al.,
2005; Gibson et al., 2008; Pertwee et al., 2010; Savinainen et al.,
2003). We designed our [35S]GTPcS binding experiments in a way
to use low concentrations of rimonabant that we either injected
intraperitoneally (alone or in combination with NE) or we directly
added to CB1 wild type (CB1+/+) and CB1 knockout (CB1/) mice
forebrain membranes. We tested CB1/CB2 double knockout mice
as well (CB1//CB2/) to elucidate the role of the CB2 receptors.
We investigated the direct binding properties of rimonabant to
MOR in receptor binding assay experiments using CB1 knockout
forebrain tissues and Chinese hamster ovary cells stably transfected
withMOR (CHO-MOR). Next, we carried out docking calculations by
docking rimonabant to a homology modeled MOR of its active and
inactive states, to gather more information about the interaction
between MOR and rimonabant.
Unspeciﬁc actions of high concentrations of rimonabant at var-
ious non-CB1 receptors are well known. This study aims to clarify
the in vivo and in vitro effects of rimonabant at MOR and MOR
mediated signaling when administered in low doses, highlights
the preferred orientations of rimonabant to MOR via in silico com-
putational simulation and tests its direct binding ability to MOR.
2. Materials and methods
2.1. Animals
CB1 receptor knockout (CB1/) mice and their controls (CB1+/+)
were generated on CD1 background in Dr. Ledent’s lab as described
in Ledent et al., 1999. CB1//CB2/ double knockout mice were
provided by Dr. Zimmer’s lab (Járai et al., 1999) and C57BL/6J mice
were used as appropriate controls (CB1+/+/CB2+/+). All the animals
were housed at 21–24 C under a 12:12 light:dark cycle and were
provided with water and food ad libitum. Different treatment
groups were composed of 7–10 animals, each. All housing and
experiences were conducted in accordance with the European
Communities Council Directives (86/609/ECC) and the Hungarian
Act for the Protection of Animals in Research (XXVIII.tv. 32.§).
2.2. Drugs and treatments
2-Arachidonyl glyceryl ether (noladin ether, NE) was purchased
from Tocris and injected at the dose of 1 mg/kg in DMSO solution.
SR141716 (rimonabant) was provided by SANOFI Research Labora-
tory (Montpellier, France) and was injected at the dose of 0.1 mg/
kg in DMSO solution. Upon acute in vivo treatments animals re-
ceived a single intraperitoneal (i.p.) injection of NE or rimonabant.
Control mice were injected with DMSO solution. When used in a
combined treatment, rimonabant was delivered 30 minutes prior
to the NE treatment as suggested by SANOFI Research Laboratory
(Rinaldi-Carmona et al., 1994). Mice were decapitated 24 h after
they received the last injection. The enkephalin analog Tyr-D-Ala-
Gly-(NMe)Phe-Gly-ol (DAMGO) was obtained from Bachem Hold-
ing AG, Bubendorf, Switzerland. [3H]DAMGO (41 Ci/mmol) and
[3H]naloxone (31 Ci/mmol) was radiolabeled in the Isotope Labora-
tory of BRC, Szeged, Hungary.
2.3. Forebrain membrane preparations
Forebrain membrane fractions from CB1/ and CB1//CB2/
mice and their controls (CB1+/+ and CB1+/+/CB2+/+, respectively) were
prepared according to the method previously described (Benyhe
et al., 1997). Brieﬂy, mice were decapitated and the brain was
quickly removed. The forebrain part was collected and homoge-
nized on ice in 50 mM Tris–HCl buffer (pH 7.4) with a Teﬂon-glass
homogenizer. The homogenate was centrifuged at 40,000g for
20 min at 4 C and the pellet was resuspended in fresh buffer
and incubated for 30 min at 37 C. This centrifugation step was re-
peated, and the ﬁnal pellet was resuspended in 50 mM Tris–HCl
buffer (pH 7.4) containing 0.32 M sucrose and stored at 80 C un-
til use.
2.4. Cell culture and cell membrane preparations
Chinese hamster ovary cells stably transfected with MORs
(MOR-CHO) were kindly provided by Dr. Zvi Vogel (Rehovot, Is-
rael). MOR-CHO cells were grown in Dulbecco’s modiﬁed Eagle’s
medium (DMEM, Gibco) and in a-minimum essential medium
(aMEM, Gibco), respectively. Both media were supplemented with
10% fetal calf serum, 2 mM glutamine, 100 IU/ml penicillin,
100 mg/ml streptomycin, 25 mg/ml fungizone and 0.5 mg/ml
geneticin. Cells were kept in culture at 37 C in a humidiﬁed atmo-
sphere consisting of 5% CO2 and 95% air.
Membranes were prepared from subconﬂuent cultures. Cells
were rinsed three times with 10 ml PBS and removed with
50 mM Tris–HCl pH 7.4, 1 mM EGTA, 1 mM EDTA and 0.1 mM
PMSF buffer and homogenized for 15 s with a polytron homoge-
nizer in an ice-bath. Homogenates were centrifuged two times at
18,000 g for 20 min. The ﬁnal pellet was resuspended in the above
buffer and stored in aliquots at 80 C until use.
2.5. Functional [35S]GTPcS binding experiments
Membrane preparations of CB1/ and CB1//CB2/ forebrains
and their proper controls were diluted in 50 mM Tris–HCl buffer
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(pH 7.4) to get appropriate protein content for the assays (10 lg
of protein/sample). Membrane fractions were incubated at 30 C
for 60 min in Tris–EGTA buffer (pH 7.4) composed of 50 mM
Tris–HCl, 1 mM EGTA, 3 mM MgCl2, 100 mM NaCl, containing
20 MBq/0.05 cm3 [35S]GTPcS (0.05 nM) and increasing concentra-
tions (1010–105 M) of DAMGO in the presence of excess GDP
(30 lM) in a ﬁnal volume of 1 ml, according to Sim et al. (1995)
and Traynor and Nahorski (1995), with slight modiﬁcations. Total
binding (T) was measured in the absence of test compounds,
non-speciﬁc binding (NS) was determined in the presence of
10 lM unlabeled GTPcS and subtracted from total binding. The dif-
ference (T–NS) represents basal activity. Bound and free
[35S]GTPcS were separated by vacuum ﬁltration throughWhatman
GF/B ﬁlters with Brandel M24R Cell harvester. Filters were washed
three times with 5 ml ice-cold buffer (pH 7.4), and the radioactivity
of the dried ﬁlters was detected in UltimaGold™ F scintillation
cocktail with Packard Tricarb 2300TR liquid scintillation counter.
Stimulation is given as percent of the speciﬁc [35S]GTPcS binding
observed in the absence of receptor ligands (basal activity).
[35S]GTPcS binding experiments were performed in triplicates
and repeated at least three times. For the in vitro experiments, fore-
brain membranes were incubated with 1010–105 M of DAMGO in
the presence or absence of 1 lM rimonabant. Log EC50 (potency)
and Emax (efﬁcacy) values were determined by GraphPad Prism 5.0.
2.6. Receptor binding assays
Aliquots of frozen CB1+/+ and CB1/ mice forebrain membranes
were centrifuged (40,000g, 20 min, 4 C) to remove sucrose and the
pellets were suspended in 50 mM Tris–HCl buffer (pH 7.4). Mem-
branes were incubated with gentle shaking at 35 C for 45 min in
a ﬁnal volume of 1 ml with unlabeled DAMGO or rimonabant
(1011–105 M) and 1 nM of [3H]DAMGO. Wild type mice fore-
brain membrane homogenates were also incubated in the presence
or absence of 10, 50 and 100 lM rimonabant together with labeled
and unlabeled DAMGO in the same experimental conditions. MOR-
CHO cell membrane fractions were incubated in a ﬁnal volume of
1 ml with 1 nM [3H]naloxone (1 nM) or 1 nM of [3H]DAMGO
and unlabeled rimonabant (1011–105 M) at 35 C for 60 min. To-
tal binding was measured in the presence of radioligand and the
non-speciﬁc binding was determined in the presence of 10 lM
unlabeled naloxone. The reaction was terminated by rapid ﬁltra-
tion under vacuum (Brandel M24R Cell Harvester), and washed
three times with 5 ml ice-cold 50 mM Tris–HCl (pH 7.4) buffer
through Whatman GF/C ([3H]DAMGO) or Whatman GF/B glass ﬁ-
bers ([3H]naloxone). The radioactivity of the dried ﬁlters was de-
tected in UltimaGold™ F scintillation cocktail with Packard
Tricarb 2300TR liquid scintillation counter. Radioligand binding as-
says were performed in duplicate and repeated at least three times.
Experimental data were analyzed by GraphPad Prism 5.0 to deter-
mine the concentration of the drug that displaced 50% of [3H]DAM-
GO (IC50).
2.7. Docking experiments
The 3D coordinates of the active and inactive conformations of
the MOR prepared by homology modeling were downloaded from
the Mosberg group’s webpage (see Web references; although the
homology model of MOR was prepared for the rat, the part of the
sequence modeled was 100% identical to that of mice). The
activated receptor model contained the MOR selective agonist,
H-Tyr-c(S-Et-S)[D-Cys-Phe-D-Pen]NH2 (JOM-6; downloaded as:
OPRM_RAT_AD_JOM6), and the inactive receptor model contained
the j-opioid antagonist, norbinaltorphimine (nor-BNI; down-
loaded as: OPRM_RAT_ID_BNI). The 3D coordinates of rimonabant,
DAMGO and naloxone were downloaded from the Cactus web site
(see Web references) using Avogadro (see Web references), the
open source chemical structure editor program. The embedded
Openbabel (O’Boyle et al., 2011) program suite was used to energy
minimize the structures with the MMFF94s (Halgren, 1999) force
ﬁeld. Ligands were prepared for docking using the AutoDockTools
(Morris et al., 2009) program suite and then docked by the program
AutoDock4 (Morris et al., 2009). In AutoDock, the maximum num-
ber of energy evaluations, the number of individuals in population
and the number of Lamarckian Genetic Algorithm runs were
250,00,000, 350 and 20, respectively to achieve an exhaustive
search for the docked poses. The size of the grid docking box was
50 Å and centered at the middle of the binding pocket. Each dock-
ing started with a random translation, rotation and torsional mod-
iﬁcation of the ligands. Results were analyzed and visualized by the
program Chimera (Pettersen et al., 2004). The receptors were kept
rigid in the docking calculations because the limitation in the num-
ber of the ﬂexible torsional angles prevented to treat the whole
binding pocket and the ligands ﬂexible simultaneously. In addition,
the docking calculations were repeated by using the ﬂexible ring
method, a speciﬁc feature of AutoDock. Calculations by AutoDock4
resulted in estimated docking free energies in kcal/mol.
3. Results
3.1. Effect of rimonabant on noladin ether caused attenuation at MOR´s
G protein activation in CB1
+/+ and CB1
/ mice forebrain membrane
fractions after a single i.p. administration
As we previously reported 24 h after a single i.p. injection of NE
at the dose of 1 mg/kg there was a signiﬁcant decrease in DAMGO-
stimulated [35S]GTPcS binding in both CB1+/+ and CB1/ mice fore-
brain. This effect was reversed partially by the CB2 antagonist
SR144528 (Páldyová et al., 2008). NE is known to be putative endo-
cannabinoid acting mainly at CB1. Rimonabant is considered to be a
selectively acting antagonist/inverse agonist at CB1 receptors. In
this experiment we co-treated CB1+/+ and CB1/ mice with NE
and rimonabant to see whether rimonabant is able to reverse NE
caused inhibition of MOR at the level of G-proteins.
Agonist-mediated G-protein activation of MOR was measured
in functional [35S]GTPcS binding experiments, in which the nucle-
otide exchange process is monitored using a non-hydrolysable
radioactive GTP analog, [35S]GTPcS. MOR was stimulated with a
highly MOR speciﬁc pure agonist peptide, DAMGO. G-protein acti-
vation can be characterized by the potency (EC50) and by the efﬁ-
cacy (also known as maximal stimulation, Emax).
During NE treatment (1 mg/kg) there was a signiﬁcant decrease
in the potency of DAMGO (0.05 lM? 1.14 lM, P < 0.001, F = 1.47,
df = 9, Fig. 1A, Table 1), and a slight but not signiﬁcant decrease in
the efﬁcacy (165.3% vs. 156.6%, Fig. 1A, Table 1), as shown previ-
ously (Páldyová et al., 2008). After injecting rimonabant at the dose
of 0.1 mg/kg prior to the NE treatment the efﬁcacy of DAMGO de-
creased even more (Emax 156.6%? 140.2%, P < 0.05, F = 1.82, df = 7,
Fig. 1A, Table 1) whereas the potency remained unaltered (1.14 lM
vs. 1.52 lM, Fig. 1A, Table 1), when compared to the single NE trea-
ted group.
In CB1 receptor deﬁcient mice single NE injection resulted a sig-
niﬁcant reduction in MOR G-protein stimulation (Emax 159%?
138.3%, P < 0.01, F = 4.02, df = 11, Fig. 1B, Table 1) but the afﬁnity
of DAMGO remained unaltered (0.45 lM vs. 0.26 lM). As it was
seen in CB1+/+ animals, rimonabant pretreatment signiﬁcantly
diminished the efﬁcacy (Emax changed 138.3%? 126.3%, P < 0.01,
F = 1.68, df = 10, Fig. 1B; Table 1), but not the potency of DAMGO
(0.26 lM vs. 0.1 lM) compared to single NE administration.
Taken together, acute i.p. injection of rimonabant prior to NE
treatment caused a prominent decrease in MOR G protein-activa-
tion in both CB1+/+ and CB1/ mice forebrain when compared to
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NE administration alone, suggesting a CB1 receptor independent
antagonizing effect of rimonabant at MOR’s activity.
3.2. Acute effect of rimonabant on DAMGO-stimulated [35S]GTPcS
binding in CB1
+/+ and CB1
/ mice forebrain membrane fractions after
a low dose i.p. administration
To conﬁrm our suggestion, namely that rimonabant has an
inhibitory action at MOR signaling, we injected CB1 deﬁcient mice
with rimonabant at the dose of 0.1 mg/kg. This concentration is at
least ten times lower than that of usually used especially when
observing the unspeciﬁc actions of this compound (Verty et al.,
2003; Beyer et al., 2010). After 24 h the mice were sacriﬁced and
the forebrain membrane fractions were tested for MOR activity
changes in [35S]GTPcS binding assay.
In CB1+/+ mice acute injection of rimonabant caused a signiﬁcant
decrease in maximal stimulation of DAMGO when compared
to vehicle injected animals (Emax changed 165.3%? 140.5%,
P < 0.001, F = 1.83, df = 13, Fig. 2, Table 2). The potency of DAMGO
did not change signiﬁcantly (0.11 lM vs. 0.17 lM, Fig. 2, Table 2).
Similarly, rimonabant administration attenuated MOR G-pro-
tein activation (Emax changed 157.2%? 140.7%, P < 0.05, F = 4.72,
df = 13, Fig. 2, Table 2) and had no signiﬁcant effect on the afﬁnity
of DAMGO in CB1/ mice forebrain membrane fractions (0.74 lM
vs. 2.2 lM, Fig. 2, Table 2).
These results show that an acute, low dose of rimonabant is
capable of attenuating DAMGO-stimulated [35S]GTPcS binding in
both CB1+/+ and CB1/ forebrain indicating a CB1 independent
action.
3.3. In vitro effect of rimonabant on DAMGO-stimulated [35S]GTPcS
binding in CB1
+/+and CB1
/ mice forebrain membrane fractions
After the in vivo studies we wanted to examine whether the
inhibition seen in MOR G-protein stimulation after acute rimona-
bant treatment can be observed when directly applying the com-
pound to forebrain membranes. For this we performed DAMGO-
stimulated [35S]GTPcS binding experiments in the presence and
absence of rimonabant using membrane preparations of untreated
CB1+/+ and CB1/ forebrain tissues (Fig. 3). We applied 1 lM of
rimonabant, which is again ten times lower concentration than
published previously by others (Cinar and Szücs, 2009).
In accordance with our in vivo data, in CB1+/+ mice we observed
a signiﬁcant decrease in the maximal stimulation of DAMGO (Emax
changed 161.7%? 143.9%, P < 0.01, F = 1.26, df = 11, Fig. 3, Table 3)
and a prominent decrease in the potency when co-applied with
rimonabant (EC50 values of DAMGO increased 0.13 lM? 1.92 lM,
n = 4, P < 0.001, Fig. 3, Table 3).
In CB1 knockouts the maximal stimulation of DAMGO at MOR´s
was also signiﬁcantly diminished by rimonabant (Emax changed to
160%? 139.9%, P < 0.05, F = 9.95, df = 10, Fig. 3, Table 3), whereas
the potency of DAMGO remained unaltered (1.65 lM vs.
1.63 lM, Fig. 3, Table 3).
Similarly to our in vivo data, in vitro administered rimonabant
causes an inhibition at MOR G-protein activation in both CB1+/+
and in CB1/ mice forebrain membranes.
3.4. In vitro effect of rimonabant on DAMGO-stimulated [35S]GTPcS
binding in CB1/CB2 double knockout mice forebrain membrane
fractions
Increasing amount of publications show the presence of CB2
cannabinoid receptors – known as the ‘‘peripheral cannabinoid
receptor’’ – in neuronal and non-neuronal cells of the central ner-
vous system. In our previous work, we have shown a CB2 mediated
NE effect on MOR signaling in mice forebrain (Páldyová et al.,
2008) as well as an inhibitory effect of a CB2 antagonist at MOR
in brainstem (Páldy et al., 2008). In this study we observed an
attenuation of rimonabant on MOR´s activity both in vivo and
in vitro not only in CB1+/+ forebrain but in CB1/ as well, suggesting
a CB1 independent action. To exclude the possible involvement of
the CB2 receptors, we used CB1/CB2 double knockout mice and per-
formed our experiments under the same conditions as seen in the
in vitro study of the CB1 single knockouts. Namely, DAMGO-stimu-
lated [35S]GTPcS binding was measured in the presence or absence
of 1 lM rimonabant on untreated CB1/CB2 double knockout fore-
brain membranes and their controls.
As it was expected applying 1 lM rimonabant to CB1+/+/CB2+/+
mice forebrain homogenates markedly attenuated the efﬁcacy of
DAMGO (194.1%? 174.3%, P < 0.01, F = 1.02, df = 6, Fig. 4, Table
4). Interestingly, the lack of both cannabinoid receptors did not
modulate the inhibitory effect of rimonabant on MOR G-protein
stimulation (200%? 178.8%, P < 0.01, F = 1.83, df = 8, Fig. 4, Table
4), therefore we can rule out the role of the CB2 receptors in the ob-
served effects.
Rimonabant’s inhibition at MORs G protein activation is very
clear after a single i.p. injection as well as after directly applied
to forebrain membranes. This effect is similar in both CB1/ single
knockout and CB1//CB2/ double knockout mice, which seem-
ingly denotes a cannabinoid receptor independent action of rimo-
nabant to MOR at G-protein level.
Fig. 1. MOR signaling in CB1+/+ (A) and CB1/ (B) mice forebrain membranes after
acute in vivo treatment with NE and combined treatment of rimonabant + NE as
described under Section 2.2. Data are presenting the speciﬁcally bound [35S]GTPcS
above basal activity in percentage during MOR activation with increasing concen-
trations of DAMGO. Points represent means ± S.E.M. for at least three experiments
performed in triplicate. The Emax and logEC50 values are shown in Table 1 with
statistical analysis.
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3.5. Direct afﬁnity measurements of rimonabant on MOR in
competition binding experiments in CB1
+/+ and CB1
/ mice forebrain
membrane fractions
Because we can exclude the role of the cannabinoid receptors
from the inhibitory actions of rimonabant on MOR signaling, we
wanted to compare the direct binding afﬁnity of rimonabant to
the MOR binding site with the highly MOR speciﬁc peptide, DAM-
GO. For this, we performed competition binding experiments with
[3H]DAMGO (1 nM) using membranes prepared from CB1+/+ and
CB1/ mice forebrain. The competing ligands were unlabeled
DAMGO or rimonabant added in increasing concentrations. Our re-
sults demonstrate that rimonabant had no speciﬁc effect on
[3H]DAMGO binding in CB1+/+ and CB1 knock-out mice. Even the
highest concentration of the CB1 antagonist rimonabant caused
only a very small, 20% reduction in [3H]DAMGO speciﬁc binding
(Fig. 5). The IC50 values of rimonabant were in the micromolar
range (in CB1+/+ mice: 9.56 lM; in CB1/ mice: 2.72 lM) which
is much higher compared to DAMGO’s (CB1+/+: 4.32 nM; CB1/:
6.41 nM). These results show that rimonabant is unable to com-
pete for the binding site of MOR at low concentrations in CB1+/+
and CB1/ mice forebrain membranes.
As it was described previously in several studies (Arnone et al.,
1997; Beyer et al., 2010; Le Foll and Goldberg, 2005; Verty et al.,
2003) rimonabant has numerous non CB1 receptor related actions
in higher concentrations. Therefore, next we wanted to investigate
how rimonabant is affecting the speciﬁc binding of DAMGO to
MOR in higher concentration. We performed homolog binding
capacity measurements but this time we added rimonabant in
every unlabeled DAMGO concentration point (Fig. 6). Applying
10 lM of rimonabant did not affect the binding of DAMGO, how-
ever in 50 and 100 lM concentrations the compound highly de-
creased the speciﬁc binding of [3H]DAMGO, nearly down to 10–
20% (Fig. 6), The observed massive reduction of [3H]DAMGO spe-
ciﬁc binding is due to the much higher applied concentration of
rimonabant compared to the administered radioligand (50 and
100 lM vs. 1 nM), that might be due to an interaction with the
membrane or ﬁlter which is a well known phenomenon. Therefore
the observed effect of rimonabant in higher concentrations can be
claimed as highly unspeciﬁc.
Our results from competition binding experiments support the
outcome of previous publications that refer to the unspeciﬁc ac-
tions of rimonabant when used in higher concentrations. Also,
when applied in lower concentrations, rimonabant is unable to
compete with DAMGO.
3.6. Docking experiments with rimonabant to inactive
and active MOR homology model
Docking, a particular ﬁeld of molecular modeling is a widely
used tool to simulate the preferred orientations of a ligand in the
binding site. Rimonabant was docked to the homology models of
the inactive and active state of the MOR. The highly speciﬁc l-ago-
nist DAMGO and the opioid speciﬁc antagonist naloxone were also
docked to the receptor models. Because DAMGO contains an N-
MePhe (N-methylphenylalanine) in its sequence, there is a possi-
bility that it adopts a cis Gly3-N-MePhe4 peptide bond (Misicka
et al., 1998). According to this, DAMGO was docked both in all-
trans form and with a cis Gly3-N-MePhe4 peptide bond (cis-DAM-
GO). Since the applied active and inactive MOR homology models
already contained JOM-6 and nor-BNI, respectively, these ligands
were also docked to the receptor models to cross validate our dock-
ing experiments. Each ligand was docked to both receptor confor-
mations to compare their preference for the speciﬁc state of MOR
(Table 5).
Docking of the ligands was performed by two methods (Table 5,
Docking experiments 1 and 2) to contract the most reliable bound
poses. The lowest docking free energies obtained were used to rank
the ability of the ligands to bind to the receptor. Additionally, an
apparent energy balance of the receptor activation process was cal-
culated for each ligand, subtracting the docking energy of the li-
gand-active receptor complex from that of the ligand-inactive
receptor complex (‘‘activation energy’’, Table 5). This value was
used to characterize the agonistic-antagonistic nature of rimona-
bant which has not been well investigated with MOR.
In the ﬁrst calculation the receptors were rigid and the ligands
were ﬂexible except that the aliphatic rings of the ligands were
kept in the conformation obtained by the energy minimization (Ta-
ble 5, Docking experiment 1). As expected during our docking
experiments JOM-6 and nor-BNI achieved the same docking poses
as published previously (Pogozheva et al., 2005). Even though
rimonabant is a highly speciﬁc CB1 receptor antagonist, the ligand
bound to the active state of MOR with surprisingly low docking
energies. Moreover, rimonabant bound to the inactive state of
Table 1
G-protein activation by the MOR agonist DAMGO in forebrain membranes of CB1+/+ and CB1/ mice after acute NE and rimonabant + NE combined treatment.
CB1+/+ mice acutely treated with CB1/ mice acutely treated with
Vehicle (control) NE Rim. + NE Vehicle (control) NE Rim. + NE
Emax ± S.E.M. (%) 165.3 ± 2.8 156.6 ± 4.7NS 140.2 ± 3.9⁄ 159 ± 3.9 138.3 ± 2.1⁄⁄⁄ 126.3 ± 2.7⁄⁄
LogEC50 ± S.E.M.
(EC50)
7.23 ± 0.11
(0.05 lM)
5.94 ± 0.15⁄⁄⁄
(1.14 lM)
5.81 ± 0.15NS
(1.52 lM)
6.34 ± 0.17
(0.45 lM)
6.58 ± 0.13NS
(0.26 lM)
6.98 ± 0.23NS
(0.1 lM)
Drugs were injected in vivo as described under Section 2.2. Forebrain membranes were used in the [35S]GTPcS binding assay with 1010–105 M concentrations of DAMGO.
The signiﬁcance level of Emax and logEC50 values are indicated by asterisks (unpaired t-test, two-tailed P value) related to the comparison of NE treatment with control, or
represents the comparison of the combined treatment (rim. + NE) with NE treatment alone. ⁄⁄⁄P < 0.001; ⁄⁄P < 0.01; ⁄P < 0.05 S.E.M.: standard error of means; NS: not
signiﬁcant; NE: noladine ether; rim.: rimonabant.
Fig. 2. MOR signaling in CB1+/+ and CB1/ mice forebrain membranes after acute
in vivo treatment with rimonabant as described under Section 2.2. Data are
presenting the speciﬁcally bound [35S]GTPcS above basal activity in percentage
during MOR activation with increasing concentrations of DAMGO. Points represent
means ± S.E.M. for at least three experiments performed in triplicate. The Emax and
logEC50 values are shown in Table 2 with statistical analysis.
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the MOR with a much lower docking energy, resulting in a positive
activation energy unlike DAMGO, cis-DAMGO and JOM-6 (Table 5).
In fact the activation energy of rimonabant was very similar to that
of the antagonist naloxone (Table 5). In the second calculation the
possibility of applying ﬂexible aliphatic rings during the experi-
ments did not improve the docking energies in general (Table 5,
Docking experiment 2).
As an important difference between the binding modes, rimo-
nabant docked to the inactive and active state of the receptor by
the opposite ends (Fig. 7A and B). Also a hydrogen bond occurs be-
tween T218 and the hydrazide group of rimonabant (Fig. 7C) in the
inactive state of the binding pocket, while no hydrogen bonds were
observed in the binding pocket of the active receptor.
Summarizing the results of our docking calculations, we ob-
served that rimonabant binds to the active conformation of MOR
with a surprisingly low energy similar to the agonist DAMGO.
However, the docking energies were even lower in the inactive
state of the MOR suggesting that rimonabant has a preference for
the inactive state of MOR. These ﬁndings raise the possibility that
rimonabant acts as an antagonist on MOR. Nevertheless, only the
inactive state gives the opportunity to form a hydrogen bond be-
tween rimonabant and one of the residues in the binding pocket.
3.7. Effect of rimonabant on MOR in competition binding experiments
in MOR-CHO cell membranes
The docking energy levels of rimonabant in the docking calcula-
tions (Table 5) pointed out that rimonabant prefers the inactive
state of MOR, which conformation is more suitable for antagonists.
To underpin the results from docking simulation we carried out
radiolabeled competition binding experiments using a tritiated
opioid antagonist [3H]naloxone to see how effectively rimonabant
is able to bind to the inactive state of MOR. The MOR agonist
[3H]DAMGO was utilized for comparison. Both tritiated ligands
were added in ﬁxed concentrations (1 nM) and incubated to-
gether with increasing concentrations of rimonabant (1011–
105 M). The experiments were performed in MOR-CHO cell mem-
branes to avoid any possible interactions with other receptors and
to measure an accurate MOR-ligand binding. We presume that the
inactive-active state of MOR will be overturned to the inactive
state when naloxone is applied and to the active state when DAM-
GO is used.
Rimonabant displaced [3H]naloxone with a signiﬁcantly lower
logIC50 value (Fig. 8, logIC50: 6.7373 ± 0.13, P < 0.001, F = 2.71,
df = 5, unpaired t-test, two-tailed P value, IC50: 0.18 lM) compared
to [3H]DAMGO (Fig. 8, logIC50: 5.75 ± 0.12, IC50: 1.74 lM), which
corresponds with our results described under Section 3.5, and also
similar to with previously reported data published by Cinar and
Szücs (2009). Moreover, the speciﬁc binding of [3H]naloxone can
be ﬁtted with the ‘‘two-site competition binding curve’’ thus the
CB1 antagonist can also displace the opioid antagonist from a dif-
ferent binding site with a high afﬁnity (Fig. 8; IC50: 0.08 nM) in
very low concentrations, although the amount of these sites are
exiguous (about 20% of the total binding site population; see
Fig. 8, shaded area).
Taken together our in silico and in vitro afﬁnity results, rimona-
bant has a higher afﬁnity to the inactive conformation state of the
MOR and has a signiﬁcantly lower binding capacity to the more
agonist favorable conformation of the receptor. Our direct afﬁnity
measurements on MOR-CHO cells also pointed out that rimona-
bant is able to bind to a high afﬁnity binding site of the MOR, in
displacing [3H]naloxone, which explains the very low docking
energies of rimonabant when it was docked in the inactive MOR.
4. Discussion
Rimonabant is considered to be an inverse cannabinoid agonist
acting selectively at CB1 receptors. In the course of time several
Table 2
G-protein activation by the MOR agonist DAMGO in forebrain membranes of CB1+/+ and CB1/ mice after acute rimonabant treatment.
CB1+/+ mice acutely treated with CB1/ mice acutely treated with
Vehicle Rimonabant Vehicle Rimonabant
Emax ± S.E.M. (%) 165.3 ± 3 140.5 ± 3.1⁄⁄⁄ 157.2 ± 2.9 140.7 ± 9⁄
LogEC50 ± S.E.M. (EC50) 6.95 ± 0.13 (0.11 lM) 6.76 ± 0.23NS (0.17 lM) 6.12 ± 0.11 (0.74 lM) 5.65 ± 0.33NS (2.2 lM)
Drugs were injected in vivo as described under Section 2.2. Forebrain membranes were used in the [35S]GTPcS binding assay with 1010–105 M concentration of DAMGO. The
signiﬁcance level of Emax and logEC50 values are indicated by asterisks (unpaired t-test, two-tailed P value), ⁄⁄⁄P < 0.001; ⁄P < 0.05 S.E.M.: standard error of means; NS: not
signiﬁcant.; rim.: rimonabant.
Fig. 3. MOR signaling in CB1+/+ and CB1/ mice forebrain membranes after in vitro
administration of rimonabant as described under Section 2.5. Data are presenting
the speciﬁcally bound [35S]GTPcS above basal activity in percentage during MOR
activation with increasing concentrations of DAMGO in the presence or absence of
1 lM rimonabant. Points represent means ± S.E.M. for at least three experiments
performed in triplicate. The Emax and logEC50 values are shown in Table 3 with
statistical analysis.
Fig. 4. MOR signaling in CB1+/+/CB2+/+ and CB1//CB2/mice forebrain membranes
after in vitro administration of rimonabant as described under as described under
Section 2.5. Data are presenting the speciﬁcally bound [35S]GTPcS above basal
activity in percentage during MOR activation with increasing concentrations of
DAMGO in the presence or absence of 1 lM rimonabant. Points represent
means ± S.E.M. for at least three experiments performed in triplicate. The Emax
and logEC50 values are shown in Table 4 with statistical analysis.
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studies have been released demonstrating numerous non-cannab-
inoid related effects of rimonabant, thus its speciﬁcity has become
questionable (reviewed in Pertwee, 2010). Very recently it was
suggested to have a bimodal proﬁle, meaning that in sub-nanomo-
lar range acts as a selective CB1 antagonist, whereas in high con-
centrations it is rather acting via CB1 independent manner
involving MOR´s as well (Raffa and Ward, 2011).
This paper is focusing on studying the effects of rimonabant in
the l-opioid system in forebrain, where CB1 and MORs are highly
co-distributed. First, changes in MOR G-protein coupling were
investigated. G-protein activation, which is the primary step in
the GPCR signaling process, was monitored in functional
[35S]GTPcS binding assays using a highly MOR speciﬁc agonist
DAMGO to activate the receptor. Previously, we have reported a
prominent decrease in DAMGO-stimulated [35S]GTPcS binding in
CB1 knockout forebrain when animals were acutely treated with
the putative endocannabinoid NE (Páldyová et al., 2008). Because
NE is known to be acting mainly at CB1 now we clariﬁed whether
rimonabant, that is considered to be a speciﬁc CB1 antagonist/in-
verse agonist, is able to reverse this effect of NE. Surprisingly en-
ough, a combined treatment with rimonabant and NE caused a
further decrease on DAMGO-stimulated MOR signaling instead of
antagonizing the effect of NE. This observation, which was similar
in both CB1 knockouts and their wild type controls, suggests that
rimonabant might have a CB1 receptor independent antagonistic
effect at MOR G-protein level.
Therefore next we tested rimonabant’s effect after a single i.p.
treatment in a 0.1 mg/kg concentration. This concentration is at
least ten times lower than that of usually applied when noting
the unspeciﬁc actions of this compound (Beyer et al., 2010; Verty
et al., 2003). In wild type mice 24 h after rimonabant treatment
DAMGO-stimulated [35S]GTPcS binding was decreased when com-
pared to vehicle treated animals. Injection of rimonabant caused a
similar impact in CB1 deﬁcient mice. These ﬁndings indicate that
an acute, low dose of rimonabant is capable of attenuating DAM-
GO-stimulated [35S]GTPcS binding in both CB1+/+ and CB1/ fore-
brain pointing out a CB1 independent action.
After the in vivo studies we wanted to know, whether rimona-
bant caused attenuation at MOR G-protein signaling is present
when directly applied to forebrain membrane homogenates. After
adding 1 lM rimonabant to wild type and CB1 knockout forebrain
membrane a signiﬁcant reduction in DAMGO-stimulated G-protein
Table 3
In vitro effect of rimonabant on DAMGO-stimulated [35S]GTPcS binding in forebrain membranes of CB1+/+ and CB1/ mice.
CB1+/+ mice CB1/ mice
Control +1 lM rim. Control +1 lM rim.
Emax ± S.E.M. (%) 161.7 ± 2.9 143.9 ± 4.9⁄⁄ 160 ± 5.7 139.9 ± 2.5⁄
LogEC50 ± S.E.M. (EC50) 6.87 ± 0.14 (0.13 lM) 5.71 ± 0.17⁄⁄⁄ (1.92 lM) 5.78 ± 0.13 (1.65 lM) 5.78 ± 0.1NS (1.63 lM)
Forebrain membranes were used from untreated CB1+/+ and CB1/ animals. Rimonabant was in vitro administered as described under Section 2.5. The signiﬁcance level of
Emax and logEC50 values are indicated by asterisks (unpaired t-test, two-tailed P value), ⁄⁄⁄P < 0.001; ⁄⁄P < 0.01; ⁄P < 0.05 S.E.M.: standard error of means; NS: not signiﬁcant;
rim.: rimonabant.
Table 4
In vitro effect of rimonabant on DAMGO-stimulated [35S]GTPcS binding in forebrain membranes of wild type and CB1//CB2/ double knockout mice.
CB1+/+/CB2+/+ mice CB1//CB2/ mice
Control +1 lM rim. Control +1 lM rim.
Emax ± S.E.M. (%) 194.1 ± 3.4 174.3 ± 3.3⁄⁄ 200 ± 3.3 178.7 ± 4.5⁄⁄
LogEC50 ± S.E.M. (EC50) 6.41 ± 0.09 (0.38 lM) 6.4 ± 0.11NS (0.39 lM) 6.75 ± 0.09 (0.17 lM) 6.45 ± 0.14NS (0.35 lM)
Forebrain membranes were extracted from untreated CB1+/+/CB2+/+ and CB1//CB2/ animals. Rimonabant was in vitro administered as described under Section 2.5. The
signiﬁcance level of Emax and logEC50 values are indicated by asterisks (unpaired t-test, two-tailed P value), ⁄⁄P < 0.01; S.E.M.: standard error of means. NS: not signiﬁcant;
rim.: rimonabant.
Fig. 5. Competition binding curves of [3H]DAMGO binding in CB1+/+ and CB1/
mice forebrain membranes as described under Section 2.6. Data are presented as
the percentage of speciﬁc [3H]DAMGO binding (1 nM) observed in the presence of
increasing concentrations of unlabeled DAMGO and rimonabant. Points represent
means ± S.E.M. for at least three experiments performed in duplicate.
Fig. 6. Competition binding curves of [3H]DAMGO binding in forebrain membranes
of wild type mice as described under Section 2.6. Data are presented as the
percentage of speciﬁc [3H]DAMGO binding (1 nM) observed in the presence of
increasing concentrations of unlabeled DAMGO and in the presence or absence of
indicated concentrations of rimonabant. Points represent means ± S.E.M. for at least
three experiments (except in the case of 50 lM rimonabant) performed in
duplicate.
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activity was observed. It is worth to note that the used concentra-
tion is again ten times lower than published previously by others
(Cinar and Szücs, 2009). These in vitro effects are in match with
those observed in vivo, showing a CB1 independent inhibitory ac-
tion of rimonabant at MOR signaling.
The exact mechanisms and interactions involved in the effects
of our in vivo data are hard to explain. However, these data serve
as an admonition indicating that a low dosage of i.p. injected rimo-
nabant has an impact on the functional activity of forebrain MORs.
Our in vitro results are easier to interpret. One plausible explana-
tion can be a cross regulation via direct interaction between
MOR and another G-protein coupled receptor, because dimeriza-
tion or oligomerization is a common occurrence between GPCRs.
According to our results it is unlikely that dimerization between
MOR and CB1 occur. However, CB2 cannabinoid receptor can be a
possible player in the observed effects. Despite of CB2 is mostly
present in non-neuronal peripheral tissues, increasing amount of
data are showing its neuronal and non-neuronal presence in the
CNS (Ross et al., 2001; Van Sickle et al., 2005). Previously we also
showed a CB2 mediated NE inﬂuence on forebrain MOR G-protein
activation (Páldyová et al., 2008) as well as an inhibitory role of a
CB2 antagonist at MOR activity in brainstem (Páldy et al., 2008).
To examine whether the CB2 receptor has a role (if any) in the ob-
served changes in MOR G-protein stimulation, in the next step we
performed DAMGO-stimulated [35S]GTPcS binding experiments on
CB1/CB2 double knockout mice forebrain. According to our data,
particularly that rimonabant decreased MOR signaling in the same
extent in double knockouts and their controls, the role of the CB2
can be excluded as well. These results were however expected
since rimonabant has a very poor afﬁnity for the CB2 receptor (Ri-
naldi-Carmona et al., 1994). Our in vitro functional [35S]GTPcS
binding results clearly indicate that rimonabant has an inhibitory
action at MORs when used in low concentrations. This effect is cor-
relative in both CB1/ single knockout and CB1//CB2/ double
knockout mice highlighting a cannabinoid receptor independent
action.
In our functional binding experiments we ruled out the involve-
ment of the cannabinoid receptors in the noted effects of rimona-
bant. But, the question whether rimonabant is able to bind directly
to MOR and therefore mediate its effect via direct coupling to MOR
remains open. To clarify this aspect, we did competition binding
experiments with tritiated opioid agonist [3H]DAMGO. In these
experiments a very high IC50 value had arose for rimonabant com-
pared to DAMGO. The afﬁnity values of rimonabant accord with
earlier binding studies (Cinar and Szücs, 2009; Kathmann et al.,
2006). In these papers, it is concluded that the CB1 antagonist binds
directly, albeit with low afﬁnity to MOR and competitively inter-
acts with [3H]DAMGO in dissociation binding experiments. Our re-
sults does not support this hypothesis, because rimonabant could
only displace [3H]DAMGO in the highest concentrations, and even
at that level it could only cause a minor decrease in the speciﬁc
binding of the radiolabeled MOR agonist. The lack of CB1 receptor
did not affect the binding characteristics of either ligand, as we
got comparable results in CB1 knockouts as well. Because previ-
ously several studies reported non CB1 receptor related actions of
rimonabant in higher concentration (Arnone et al., 1997; Beyer
et al., 2010; Le Foll and Goldberg, 2005; Verty et al., 2003), we
tested the binding properties of DAMGO in the presence of highly
concentrated rimonabant as well. In these experiments 50 and
100 lM of rimonabant decreased the 1 nM [3H]DAMGO binding
approximately to non-speciﬁc binding level, at the same time at
10 lM concentrations rimonabant remained effectless. In sum-
mary, rimonabant cannot compete for the binding site of MOR at
low concentrations and it is unspeciﬁc in higher concentrations.
Docking calculations gives the opportunity to gather informa-
tion about the receptor–ligand complex, such as the estimate of
binding energy, the possible intermolecular interactions, orienta-
tions or the occurring energy alterations, which are hard to achieve
in in vitro studies. Rimonabant accommodates to both receptor
conformations with a low docking energy (which was unexpect-
edly low in the case of the active state), but with a high energy ex-
pense for the activated receptor compared to the inactive one,
suggesting an antagonistic character for the ligand. This is sup-
ported by our ﬁnding that only the inactive state gives the possibil-
ity for a hydrogen bond between rimonabant and a residue in the
binding pocket of MOR.
To support the docking results, we carried out radiolabeled
competition binding experiments using a tritiated opioid antago-
nist [3H]naloxone to see how effectively rimonabant is able to bind
to the inactive state of MOR. To exclude any possible interactions
with other receptors, for the experiments we used CHO-MOR cells.
[3H]naloxone was given in a 1 nM ﬁxed concentration and was
incubated together with increasing concentrations of rimonabant.
Rimonabant was able to displace [3H]naloxone with a signiﬁcantly
lower logIC50 value compared to [3H]DAMGO. Moreover a higher
afﬁnity binding site for rimonabant was measured in the displace-
ment of [3H]naloxone. The high and low afﬁnity binding sites are
common in GPCRs (Baker and Hill, 2007), and previously our group
had demonstrated it on opioid receptors, including on the MOR
(Krizsán et al., 1991). The high binding energies of rimonabant
docked to the activated MOR still remains to be understood. A
possible explanation is that rimonabant is accepted by MOR in
Table 5
Docking energies and the calculated activation energy of rimonabant compared to naloxone, DAMGO, cis-DAMGO, JOM-6 and nor-BNI during the indicated docking experiments
in inactive and active MOR.
Docking experiments Ligands Docking energy Activation energy
MOR inactive MOR active
1. Rigid receptor, rigid ring Rimonabant 12.70 10.94 1.76
Naloxone 10.44 8.73 1.71
DAMGO 10.40 11.44 1.04
cis-DAMGO 9.99 10.61 0.62
JOM-6 10.27 13.88 3.61
Nor-BNI 18.35 8.58 9.77
2. Rigid receptor, ﬂexible ring Rimonabant 12.56 10.94 1.62
Naloxone 10.46 8.74 1.72
DAMGO 8.70 9.14 0.44
cis-DAMGO 10.59 10.81 0.22
JOM-6 11.26 13.91 2.65
Nor-BNI 18.35 8.57 9.78
The 3D coordinates of the inactive and active conformations of MOR, and the preparations of the ligands for docking are described under Section 2.7. Activation energy was
calculated by subtracting the docking energy of the activated MOR from that of the inactive MOR. The data are represented in kcal/mol.
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its resting (inactive) state which is maintained by bound naloxone,
including the high afﬁnity state. This is in accordance with its low-
er docking energies to the inactive receptor compared to that of
naloxone. The subsequent receptor activation is prevented by the
energy barrier restricting rimonabant as an antagonist. Contrary
to these, bound DAMGOmaintains the receptor in its active confor-
mation and the high afﬁnity binding site related to the inactive
state is not present in the otherwise small ligand free population
of MOR which released DAMGO. Nevertheless the inhibitory ac-
tions of rimonabant upon MOR G-protein stimulation could be
interpreted with its antagonistic behavior on MOR.
Since rimonabant was ﬁrst described as the potent CB1 receptor
antagonist, it is widely used for blocking cannabimimetic effects
via blocking CB1 receptor mediated signaling pathways (for review
see Pertwee, 2005), due to its very high afﬁnity towards CB1 recep-
tor. However growing number of evidences is showing that CB1
speciﬁc compounds conspicuously act in a CB1 independent man-
ner, including rimonabant. There are several publications support-
ing that rimonabant can bind with low afﬁnity to other GPCRs,
including j-opioid receptors, GPR55 or can activate several types
of ion channels, among others (for review see Pertwee, 2010). In
our study we emphasize that rimonabant is able to inhibit the
functional activity of forebrain MORs in low concentrations both
in vivo and in vitro. This inhibition is CB receptor independent
and comprises MOR’s where rimonabant acts as a MOR antagonist
on a higher afﬁnity binding site. However, our in vivo data under-
line another, most likely indirect a possible direct mechanisms that
are additionally involved in the observed effects. This can be due to
a wild range of cross talks that occur in the signaling pathways of
GPCRs, which in consequence might activate a ray of entirely new
pathways. Because CB1 receptors are the most widely distributed
Fig. 7. The docking pose of rimonabant in the inactive (A) and active (B) MOR, and the hydrogen bond between rimonabant and T218 (C). Rimonabant is indicated in yellow
(the nitrogen and hydrogen atoms of the hydrazide group are shown in blue and white, respectively). The hydrogen bond is highlighted with a black dotted line; the hydrogen
acceptor (oxygen) is shown in red on T218. The essential extracellular loops (ECL) and transmembrane regions (TM) are indicated on the inactive conformation of MOR for
clarity.
Fig. 8. Competition binding curves of [3H]naloxone and [3H]DAMGO binding in
MOR-CHO cell membranes as described under Section 2.6. Data are presented as the
percentage of speciﬁc radioligand binding (1 nM) observed in the presence of
increasing concentrations of unlabeled rimonabant. The shaded area indicates the
high afﬁnity binding site of the curve. Points represent means ± S.E.M. for at least
three experiments performed in duplicate.
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GPCRs in the brain, unspeciﬁc actions of rimonabant are inevitable.
This assumption is underpinned by our study along with others.
Despite of being far from the complete understanding of the exact
mechanisms behind the impact of rimonabant on the opioid sys-
tem, our data presented above partially elucidate its actions.
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a b s t r a c t
What is known: There is a growing number of evidence showing, that the cannabinoid receptor 1 (CB1)
antagonist rimonabant has many non-cannabimimetic actions, such as affecting the opioid system. The
direct effect of rimonabant on opioid receptors has been studied so far mainly on l-opioid receptors.
However recently the d-opioid receptor (DOR) receives much more attention as before, due to its poten-
tial therapeutic applications, such as nociception or treatment for psychiatric disorders.
Objectives: To investigate the direct effect of rimonabant on DOR speciﬁc ligand binding and on the DOR
mediated G-protein activation.
Results: Micromolar concentrations of rimonabant directly inhibited the DOR speciﬁc agonist binding in
radioligand competition binding experiments using Chinese hamster ovary cells stably transfected with
mouse DOR (CHO-mDOR). However the inhibition occurred also in the subnanomolar range during DOR
speciﬁc antagonist binding in similar experimental conditions. In functional [35S]GTPcS binding assays
rimonabant signiﬁcantly decreased the basal receptor activity in CHO-mDOR but also in parental CHO cell
membranes. During DOR agonist stimulation, micromolar concentration of rimonabant attenuated the
DOR G-protein activation and the potency of the activator ligand in [35S]GTPcS binding assays performed
in CHO-mDOR, in wild type and also in CB1/CB2 double knock-out mouse forebrain membranes. Yet again
this inhibitory action was DOR speciﬁc, since it did not occur during other speciﬁc GPCR agonist mediated
G-protein activation.
Conclusion: Rimonabant directly inhibited DOR function in the micromolar concentrations. The inhibi-
tory actions indicate an antagonistic behavior towards DOR which was established by the followings:
(i) rimonabant inhibited DOR antagonist binding more effectively than agonist binding, (ii) the inverse
agonistic, agonistic effect of the compound can be excluded, and (iii) additionally according to previous
ﬁndings the allosteric mechanism can also be foreclosed.
 2013 Elsevier Ltd. All rights reserved.
1. Introduction
Among the opioid receptors, l, d and j (MOR, DOR and KOR,
respectively), the DOR is relatively studied in a less extent com-
pared to its two other companions, especially to MOR (Pradhan
et al., 2012). However recently there is an increasing number of
studies showing DOR as a potential therapeutic target (for review
see Pradhan et al., 2011), more interestingly the activation of
DOR represents less of the known adverse effects of MOR stimula-
tion such as addiction, respiratory depression, or constipation
(Codd et al., 2009). Additionally certain DOR agonists have anxio-
lytic and anti-depressant effects too (Broom et al., 2002; Perrine
et al., 2006; Saitoh et al., 2004).
Both cannabinoid receptor types – type 1 (CB1) and type 2 (CB2)
– share many features with the opioid receptors: they all belong to
the G-protein coupled receptor (GPCR) superfamily, and couple
http://dx.doi.org/10.1016/j.neuint.2013.12.005
0197-0186/ 2013 Elsevier Ltd. All rights reserved.
Abbreviations: [35S]GTPcS, guanosine-50-O-(3-[35S]thio)triphosphate; BBB,
blood–brain-barrier; CB1, type 1 cannabinoid receptor; CB1/CB2 K.O., CB1/CB2
double knock-out; CB2, type 2 cannabinoid receptor; CHO, Chinese hamster ovary
cell line; CHO-mDOR, Chinese hamster ovary cell line overexpressed with mouse
d-opioid receptor; CHO-MOR, Chinese hamster ovary cell line overexpressed with
l-opioid receptor; DMSO, dimethyl sulphoxide; DOR, d-opioid receptor; DPDPE,
[D-Pen2,5]-enkephalin hydrate; EGTA, ethyleneglycol-tetraacetate; GDP, guanosine
50-diphosphate; GPCR, G-protein coupled receptor; GTP, guanosin 50-triphosphate;
GTPcS, guanosine-50-O-[c-thio] triphosphate; KOR, j-opioid receptor; MOR,
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mainly to the Gi/o type G-proteins (Burford et al., 2000; Demuth
and Molleman, 2006), therefore they inhibit the release of different
types of neurotransmitters such as GABA, glutamate, noradrena-
line, acetylcholine or dopamine (Howlett et al., 2002; Katona
et al., 1999; Mansour et al., 1995; Shen et al., 1996). Furthermore
their distribution overlaps in certain brain regions such as cerebral
cortex or amygdala (Gong et al., 2006; Howlett et al., 2002; Man-
sour et al., 1995; Sim and Childers, 1997). The CB1 receptor and
DOR have not only similar functions, like nociception (Bie and
Pan, 2007; Bushlin et al., 2012; Maldonado and Valverde, 2003;
Pertwee, 2001) and mood regulation (Bambico et al., 2007; Filliol
et al., 2000), but they can allosterically alter each other’s activity
(Berrendero et al., 2003; Bushlin et al., 2012; Rozenfeld et al.,
2012; Urigüen et al., 2005) and form heteromers as well (Bushlin
et al., 2012).
The CB1 receptor is known for having a well-established role in
appetite control (for review see Pagotto et al., 2006), thus both CB1
agonists and antagonist are developed for therapeutic control of
food intake (for review see Lee et al., 2009; Pagotto et al., 2006).
The chief among the CB1 receptor antagonists, rimonabant was
ﬁrstly developed (Rinaldi-Carmona et al., 1994) and marketed as
an appetite suppressant under the trade name Acomplia (Padwal
and Majumdar, 2007). However 2 years after its introduction it was
withdrawn from the market because serious psychiatric side ef-
fects such as severe depression, anxiety and suicidal thoughts oc-
curred during chronic administration of the drug (see web
reference). Before and also after the withdrawal, preclinical rodent
studies showed both anxiolytic/antidepressant and anxiogenic ef-
fects and depression-like behavior during acute rimonabant
administration (Arévalo et al., 2001; Lockie et al., 2011; McGregor
et al., 1996; Rodgers et al., 2003; Tzavara et al., 2003), while
chronic treatment of rimonabant clearly induced depression-like
behavior in the animals (Beyer et al., 2010). Although rimonabant
is believed to behave as an antagonist on CB1 receptor, there are
increasing numbers of studies reporting that it can inhibit CB1
receptor mediated G-protein basal activity (Breivogel et al., 2001;
MacLennan et al., 1998; Sim-Selley et al., 2001), thus it can behave
as an inverse agonist. This character of rimonabant results in oppo-
site cannabimimetic effects to that of a CB1 agonist, such as en-
hanced neurotransmitter release, increased memory activity or
even reduced food consumption (for review see Pertwee, 2005).
However later on the inverse agonistic actions of rimonabant has
been proven to be CB1 receptor independent, probably occurring
via non-receptor mediated manner or allosterically on CB1 receptor
or through other GPCRs different from CB1 receptor (Breivogel
et al., 2001; Cinar and Szücs, 2009; Seely et al., 2012; Sim-Selley
et al., 2001).
Rimonabant can interact with other members of the GPCR fam-
ily, such as opioid receptors (for review see Pertwee, 2010). It has
been shown that it can affect the function of MOR through the CB1
receptor (for review see Foll and Goldberg, 2005 and Robledo et al.,
2008), moreover there is an increasing number of studies reporting
a direct effect of rimonabant on opioid receptors, mainly focusing
on MORs (Cinar and Szücs, 2009; Fong et al., 2009; Kathmann
et al., 2006; Seely et al., 2012; Zádor et al., 2012). Recently our
group also demonstrated an antagonistic character of rimonabant
on MOR (Zádor et al., 2012) which was later afﬁrmed by Seely
and coworkers (Seely et al., 2012).
The aim of this study was to examine the direct effect of rimo-
nabant on DOR function, since this opioid receptor type is not well
studied in this aspect yet. Herein we investigated the effect of
rimonabant on DOR speciﬁc ligand binding and for the ﬁrst time
on DOR G-protein basal activity and on DOR G-protein activity dur-
ing agonist-stimulation. Furthermore we clariﬁed the role of both
cannabinoid receptors in the forebrain region regarding to the ef-
fect of rimonabant on DOR functionality.
2. Materials and methods
2.1. Chemicals
Tris–HCl, EGTA, NaCl, MgCl2  6H2O, GDP, the GTP analog
GTPcS, the adrenerg receptor agonist L-epinephrine, the DOR spe-
ciﬁc agonist peptide DPDPE, the DOR antagonist naltrindole and
the KOR speciﬁc agonist U50488 were purchased from Sigma–Al-
drich (St. Louis, MO, USA). The MOR agonist morphine was ob-
tained from the Alkaloid Chemic Factory (Tiszavasvár, Hungary).
The radiolabelled GTP analog, [35S]GTPcS (speciﬁc activity:
>1000 Ci/mmol) was purchased from the Isotope Institute Ltd.
(Budapest, Hungary). SR141716 (rimonabant) was acquired from
Santa Cruz (Dallas, Texas, USA). The modiﬁed DOR speciﬁc deltor-
phin II derivative, Ile5,6deltorphin II was synthesized and tritiated
([3H]Ile5,6deltorphin II; speciﬁc activity: 28 Ci/mmol; Nevin et al.,
1994) in the Isotope Laboratory of Biological Research Center (Sze-
ged, Hungary). The opioid antagonist naloxone was kindly provided
by the company Endo Laboratories DuPont de Nemours (Wilming-
ton, DE, USA). [3H]naltrindole ([3H]NTI; speciﬁc activity: 24 Ci/
mmol) was purchased from PerkinElmer (Boston, USA). Rimonabant
was dissolved in DMSO and similar to the other applied receptor
ligands, was stored in 1 mM stock solution at 20 C.
2.2. Animals
The CB1/CB2 receptor double knockout mice were provided by
Dr. Andreas Zimmer’s laboratory (University of Bonn, Germany),
the lack of both cannabinoid receptors was conﬁrmed in previous
studies (Járai et al., 1999). The wild type mice were bought from
the local animal house of the Biological Research Center (Szeged,
Hungary). Both mice genotypes were derived from the C57BL/6J
strain and 8 wild type and 8 double knock-out animals were used
for membrane preparations. All the animals were housed at 21–
24 C under a 12:12 light: dark cycle and were provided with water
and food ad libitum. All housing and experiences were conducted in
accordance with the European Communities Council Directives
(86/609/ECC) and the Hungarian Act for the Protection of Animals
in Research (XXVIII.tv. 32.§).
2.3. Cell culture and cell membrane preparations
CHO-mDOR cells overexpressing mouse DORs were provided by
Dr. Zvi Vogel (Rehovot, Israel). The maximal DOR binding capacity
in the cell lines was 2730 ± 90 fmol/mg according to our group’s
previous reports (Ioja et al., 2007, 2005).
The growing of the cells was performed as we previously de-
scribed (Zádor et al., 2012). Brieﬂy the cells were grown in Dul-
becco’s modiﬁed Eagle’s medium and in a-minimum essential
medium, respectively. Both media were supplemented with 10%
fetal calf serum, 2 mM glutamine, 100 IU/ml penicillin, 100 mg/
ml streptomycin, 25 mg/ml fungizone and 0.5 mg/ml geneticin.
Parental CHO cells (pCHO) were cultured in F-12 medium with L-
glutamine which contained 10% fetal bovine serum. Both CHO cell
lines were kept in culture at 37 C in a humidiﬁed atmosphere con-
sisting of 5% CO2 and 95% air.
Cell membranes were prepared for competition binding exper-
iments as we previously described (Zádor et al., 2012). For the
[35S]GTPcS binding assays the membrane homogenate was pre-
pared similarly except the cells were diluted in TEM buffer
(50 mM Tris–HCl, 1 mM EGTA, and 5 mM MgCl2; pH 7.4).
2.4. Forebrain membrane preparations
Forebrain membrane fractions from CB1/CB2 K.O. mice and their
wild type controls were prepared according to the method
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previously described (Benyhe et al., 1997) until the point where
the membrane homogenate was prepared for the [35S]GTPcS
binding assay. In this procedure the sucrose was removed by
centrifugation (40,000g, 20 min, 4 C) and the pellet was
suspended with ice-cold TEM buffer to obtain the appropriate
protein content for the assay (10 lg/ml).
2.5. Radioligand competition binding assays
The direct binding afﬁnity of rimonabant towards DOR was
investigated in radioligand competition binding experiments,
where we measure the inhibition of ﬁx concentrations of speciﬁc
radioligand binding in the presence of increasing concentrations
of unlabeled competitor ligands.
Aliquots of frozen pCHO and CHO-mDOR membranes were ﬁrst
centrifuged (40,000g, 20 min, 4 C) to remove sucrose and the pel-
lets were suspended in 50 mM Tris–HCl buffer (pH 7.4). Mem-
branes were incubated with gentle shaking at 35 C for 35 min
([3H]Ile5,6deltorphin II) or 25 C for 60 min ([3H]NTI) in a ﬁnal vol-
ume of 1 ml with 1010 to 105 M concentration interval of unla-
beled rimonabant together with 1 nM of [3H]Ile5,6deltorphin II
or [3H]NTI. Total binding was measured in the presence of radioli-
gand, in the absence of the competitor ligands. The non-speciﬁc
binding was determined in the presence of 10 lM unlabeled nalox-
one. The reaction was terminated by rapid ﬁltration under vacuum
(Brandel M24R Cell Harvester), and washed three times with 5 ml
ice-cold 50 mM Tris–HCl (pH 7.4) buffer through Whatman GF/C
([3H]Ile5,6deltorphin II) or GF/B ([3H]NTI; washed in 3% polyethy-
lenimine for 60 min) glass ﬁber ﬁlters. The radioactivity of the ﬁl-
ters was detected in UltimaGold™ MV aqueous scintillation
cocktail with Packard Tricarb 2300TR liquid scintillation counter.
The competition binding assays were performed in duplicate and
repeated at least three times.
2.6. Functional [35S]GTPcS binding assays
The G-protein activation of DOR was measured in functional
[35S]GTPcS binding experiments, which monitors the nucleotide
exchange process of the Ga-protein using a non-hydrolysable radi-
olabeled GTP analog, [35S]GTPcS in the presence of increasing con-
centrations of the observed ligand.
The assays were performed according to previous studies (Sim
et al., 1995; Traynor et al., 1995), with slight modiﬁcations. Mem-
brane fractions of pCHO, CHO-mDOR and CB1/CB2 K.O. and wild
type mouse forebrains were incubated in a ﬁnal volume of 1 ml
at 30 C for 60 min in Tris-EGTA buffer (pH 7.4) composed of
50 mM Tris–HCl, 1 mM EGTA, 3 mMMgCl2, 100 mM NaCl, contain-
ing 0.05 nM [35S]GTPcS (20 MBq/0.05 cm3) and 30 lM GDP to-
gether with the indicated concentrations of DPDPE, rimonabant,
NTI, U50488, morphine or L-epinephrine. Total binding (T) was
measured in the absence of the ligands, non-speciﬁc binding (NS)
was determined in the presence of 10 lM unlabeled GTPcS and
subtracted from total binding. The difference (TNS) represents ba-
sal activity. Bound and free [35S]GTPcS were separated by vacuum
ﬁltration through Whatman GF/B ﬁlters with Brandel M24R Cell
harvester. Filters were washed three times with 5 ml ice-cold buf-
fer (pH 7.4), and the radioactivity of the dried ﬁlters was detected
in UltimaGold™ MV scintillation cocktail with Packard Tricarb
2300TR liquid scintillation counter. The [35S]GTPcS binding exper-
iments were performed in triplicates and repeated at least three
times.
2.7. Data analysis
Experimental data were presented as means ± S.E.M. and were
ﬁtted with the professional curve ﬁtting program, GraphPad Prism
5.0 (GraphPad Prism Software Inc., San Diego, CA), using non-linear
regression. During the competition binding assays the ‘One site
competition’ or in the case of [3H]NTI displacement studies the
‘Two sites-Fit logIC50’ ﬁtting equation was applied to determine
the concentration of the competitor ligands that displaced 50% of
the radioligand (IC50). The inhibition of speciﬁcally bound
[3H]Ile5,6deltorphin II and [3H]NTI was given in percentage, the to-
tal speciﬁc binding and the minimum level of non-speciﬁc binding
was deﬁned as 100% and 0% respectively. Additionally competition
binding experiments applied in pCHO cell membranes the bound
[3H]Ile5,6deltorphin II was represented in cpm (counts per minute)
since there was no speciﬁc binding observed in this experiments
(see Fig. 1A). In the [35S]GTPcS binding assays the ‘Sigmoid dose-
response’ ﬁtting was used to establish the maximal stimulation
or efﬁcacy (Emax) of the receptors G-protein, and the potency
(EC50) of the stimulator ligand. Stimulation was given as percent
of the speciﬁc [35S]GTPcS binding observed over or under the basal
activity, which was settled as 100%. In case of two data sets un-
paired t-test with two-tailed P value statistical analysis was used,
while in case of three or more data sets One-way ANOVA with Bon-
ferroni’s Multiple Comparison post hoc test was performed to
determine the signiﬁcance level, using GraphPad Prism 5.0. Since
both the competitor and stimulator ligands were presented in
the logarithm form, the curve ﬁtting program could only calculate
S.E.M. for the logarithm form of IC50 (logIC50) and EC50 (logEC50)
values. At the same time their antilogarithm form has also been
indicated on the ﬁgures for better understanding. Signiﬁcance
was accepted at the P < 0.05 level.
3. Results
3.1. Direct binding afﬁnity measurements of rimonabant towards DOR
in competition binding experiments in CHO-mDOR membrane
fractions
Our ﬁrst objective was to measure the binding afﬁnity of rimo-
nabant directly towards DOR. Equilibrium competition binding
experiments were carried out with the DOR speciﬁc tritiated ago-
nist Ile5,6deltorphin II ([3H]Ile5,6deltorphin II) using membrane
fractions of CHO cells overexpressing mouse DOR (CHO-mDOR)
to insure a better receptor-ligand interaction. Additionally we also
applied the DOR speciﬁc tritiated antagonist naltrindole ([3H]NTI)
to see whether rimonabant can alter agonist or antagonist speciﬁc
binding differently on DOR. Initially we determined the presence of
DOR binding in parental CHO (pCHO) cell lines, which were not
overexpressed with DORs. According to our results no signiﬁcant
displacement was observed between [3H]Ile5,6deltorphin II and
unlabeled Ile5,6deltorphin II (Fig. 1A), therefore the points could
not be ﬁtted with non-linear regression. Additionally similar
[3H]Ile5,6deltorphin II binding values were detected in the presence
of unlabeled Ile5,6deltorphin II and 10 lMnaloxone (Fig. 1A), which
is applied for the calculation of non-speciﬁc binding (see Sec-
tion 2.5). Thus the detected bound [3H]Ile5,6deltorphin II was due
to non-speciﬁc binding. Accordingly we can conclude that in pCHO
cell lines DOR are not expressed physiologically.
Rimonabant reduced the total speciﬁc binding (=100%) of the
agonist [3H]Ile5,6deltorphin II only in micromolar concentrations
(Fig 1B). In 10 lM concentrations the speciﬁc binding of the radio-
ligand was inhibited approximately 50% (Fig. 1B) resulting a
2.8 lM IC50 value for rimonabant (Fig 1C). During the displacement
of the antagonist [3H]NTI – similar to [3H]Ile5,6deltorphin II – rimo-
nabant at the highest applied concentrations reduced the total spe-
ciﬁc binding of the radioligand approximately 50% (Fig. 1B).
However interestingly rimonabant also inhibited the total speciﬁc
[3H]NTI binding in the nanomolar range (1010 to 109 M), which
was followed by a short plateau phase (109 to 107 M) and in
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the micromolar range the speciﬁc binding was again decreased (Fig
1B). The ‘‘two phase’’ inhibition suggests a higher and a lower
afﬁnity binding site on the DOR, which can be both occupied by
rimonabant with a subnanomolar (high afﬁnity) and micromolar
(low afﬁnity) IC50 value (Fig. 1C).
Thus in the micromolar range rimonabant can affect the ligand
binding of DOR directly, moreover rimonabant can also inhibit spe-
ciﬁc antagonist binding in the nanomolar range with very high
afﬁnity. Accordingly rimonabant might behave as an antagonist to-
wards DOR, since it can inhibit DOR antagonist binding more
effectively.
3.2. The effect of rimonabant on DOR G-protein basal activity in
[35S]GTPcS binding assays, in CHO-mDOR and pCHO cell membranes
In the next step we examined whether rimonabant alters the
basal activity of the DOR mediated G-protein stimulation in func-
tional [35S]GTPcS binding experiments, with a non-hydrolysable
radiolabeled GTP analog, [35S]GTPcS. The experiments were
accomplished in CHO-mDOR and pCHO cell membranes, to avoid
interaction of DORs with other opioid and cannabinoid receptors,
and also to see clearly the direct actions of rimonabant on DOR
G-protein coupling.
According to our results rimonabant signiﬁcantly decreased the
DORs basal activity (=100%, dotted line; Fig. 2A), with an efﬁcacy
(Emax) of 48.1% and with a potency (EC50) of 1.3 lM (Fig. 2A, inset
ﬁgure). Thus rimonabant may behave as an inverse agonist at DOR.
To investigate whether the inverse agonistic effect of rimona-
bant on DOR is indeed DOR related, we measured the speciﬁcally
bound [35S]GTPcS when 10 lM rimonabant was incubated to-
gether with 1 lM of the DOR speciﬁc antagonist naltrindole again
in CHO-mDOR cell membranes. Our results pointed out that NTI
failed to reverse the inverse agonistic effect of rimonabant
(Fig. 2B), therefore DOR is not involved in this action. For compar-
ison, NTI signiﬁcantly inhibited DPDPE-stimulated [35S]GTPcS
binding (Fig. 2B). Also the MOR agonist morphine and the KOR ago-
nist U50488, together with NTI failed to alter the G-protein basal
activity of DOR signiﬁcantly (Fig. 2B). This conﬁrms the lack of both
MOR and KOR in the CHO-mDOR cell membranes, and the pure
antagonistic character of naltrindole. Additionally rimonabant also
signiﬁcantly decreased G-protein basal activity in pCHO cell mem-
branes (Fig 2C, inset ﬁgure), which did not contain DORs (DPDPE
did not alter basal activity, see Fig. 2C), which underpins the
non-DOR related inverse agonistic effect of rimonabant.
3.3. The effect of rimonabant on DOR G-protein activation in DPDPE-
stimulated [35S]GTPcS binding, in CHO-mDOR cell membranes
Since rimonabant directly inhibited DORs ligand binding in the
micromolar range, we further examined whether rimonabant at
the same concentration range has any effect on DORs G-protein
activation during receptor stimulation. The experiments were
again accomplished in functional [35S]GTPcS binding experiments
using CHO-mDOR cell membranes. The receptor was stimulated
with the enkephalin analog DOR speciﬁc agonist DPDPE, which
activated the DOR the most effectively compared to our other
DOR activator ligand candidates (data not shown).
DPDPE stimulated the DOR with a potency (EC50) of 12.4 nM
and the receptors G-protein had a maximal stimulation or efﬁcacy
(Emax) of 285.6% during DPDPE stimulated receptor activation
(Fig. 3A–C). Rimonabant in 1 and 10 lM concentrations signiﬁ-
cantly decreased the DORs G-protein efﬁcacy (Fig. 3B) and
also the potency of DPDPE but only in 10 lM concentrations
(Fig. 3C).
Fig. 1. Direct binding afﬁnity measurements of rimonabant towards DOR in competition binding experiments in CHO-mDOR membrane fractions and DOR speciﬁc ligand
binding in pCHO cell membranes. (A) Bound [3H]Ile5,6deltorphin II in counts per minute (cpm) in ﬁxed concentrations in the presence of increasing (1010 to 105 M)
concentrations of unlabeled DPDPE and 10 lM naloxone in pCHO cell membranes. (B) Speciﬁcally bound ﬁxed concentrations of [3H]Ile5,6deltorphin II or [3H]naltrindole in
percentage in the presence of increasing (1010 to 105 M) concentrations of unlabeled rimonabant in CHO-mDOR membrane fractions. (C) The calculated logIC50 (binding
capacity) of unlabeled rimonabant. Points and columns represent means ± S.E.M. for at least three experiments performed in duplicate. ‘‘Total’’ on the X axis refers to the
points which did not contain competitor ligands and also represents the total speciﬁc binding (=100%, indicated by the dotted line) in the presence of either radioligand.
Additionally the level of 50% DOR speciﬁc radioligand binding is represented with a dotted line. The two black columns indicate the logIC50 values of rimonabant on the high
and low afﬁnity binding sites. The antilogarithm form of logIC50 (IC50) values are presented in brackets.
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Thus rimonabant inhibited the DPDPE-induced maximal G-pro-
tein stimulation of the DOR and also the potency of the stimulator
ligand in the micromolar range when no cannabinoid or other opi-
oid receptors were present in the experimental system.
3.4. The effect of rimonabant on DOR G-protein activation in DPDPE-
stimulated [35S]GTPcS binding, in wild type and CB1/CB2 receptor
double knock-out mouse forebrain membranes
Our next objective was to examine whether the inhibitory ac-
tion of rimonabant upon DOR G-protein activation and stimulatory
ligand potency occurs when the receptor is expressed in physiolog-
ical conditions, when cannabinoid and other opioid receptors are
present, thus interactions may occur between them. Membrane
fractions of mice forebrain were used, since both opioid and can-
nabinoid receptors are expressed in eligible amount in this brain
region (Lever, 2007; Sim and Childers, 1997; Svízenská et al.,
2008). Since the inhibitory actions of rimonabant occurred from
1 lM in CHO-mDOR cell membranes, we carried out our further
experiments with this concentration.
In the wild type (w.t.) mouse forebrain DPDPE stimulated the
DOR to a maximal stimulation level of 138.1% with an EC50 value
of 13.8 nM (Fig. 4A–C). The presence of rimonabant produced a sig-
niﬁcant attenuation in the maximal efﬁcacy of DORs G-protein
activity (Fig. 4A and B) and in the potency of the stimulatory ligand
as well (Fig. 4C).
Previously our group demonstrated an interaction between the
CB2 receptor and MOR in mice forebrain (Páldyová et al., 2008)
therefore we studied the possible role of the CB1 receptor in the
inhibitory actions of rimonabant, and also the role of the CB2 recep-
tor. To achieve this, we carried out our DPDPE-induced [35S]GTPcS
binding assays in CB1/CB2 K.O. mouse forebrain membranes.
Accordingly the reduced maximal efﬁcacy of the receptor and the
potency of the activating ligand (Fig. 4A–C, respectively) were also
established in the CB1/CB2 K.O. mouse forebrain when rimonabant
was added. Interestingly in the absence of rimonabant, the lack of
both cannabinoid receptors did not affect signiﬁcantly the maximal
stimulation of the G-protein activity or the stimulatory potency of
DPDPE (Fig. 4A–C).
Further on we wanted to verify that the inhibitory actions of
rimonabant are not due to the unspeciﬁc inverse agonistic effect
discussed previously under Section 3.2. To exclude this possibility
we applied L-epinephrine, which is a non-selective endogenous
adrenergic receptor agonist, in [35S]GTPcS binding assays in
CB1/CB2 K.O. mouse forebrain membranes. Adrenergic receptors
are highly expressed in the forebrain structures and can coupled
to Gi/o type G-proteins such as the a2 type receptors (Cottingham
and Wang, 2012), therefore they can be monitored by L-epineph-
rine-stimulated [35S]GTPcS binding assays. L-epinephrine activated
its speciﬁc receptor with a 31.6 nM potency (Fig. 5C) and the cou-
pled G-protein had a 166.8% maximal efﬁcacy during the activation
(Fig. 5A and B). In the presence of 10 lM rimonabant neither of the
parameters changed signiﬁcantly (Emax: 162%; EC50: 26.7 nM;
Fig. 5A–C), thus the inhibitory actions of rimonabant are indeed
DOR speciﬁc.
To summarize the DPDPE-activated [35S]GTPcS binding experi-
ments accomplished in the forebrain, we can conclude that
rimonabant inhibits agonist-stimulated DOR G-protein efﬁcacy
Fig. 2. The effect of rimonabant on DOR G-protein basal activity in ligand-modulated [35S]GTPcS binding assays, in CHO-mDOR and in pCHO cell membranes. (A) Speciﬁcally
bound [35S]GTPcS in percentage in the presence of increasing concentrations (1010 to 105 M) of rimonabant in CHO-mDOR cell membranes. Emax and logEC50 values are
presented in the inset ﬁgure. ⁄Denotes the signiﬁcant alterations of DOR G-protein Emax value (unpaired t-test, two-tailed P value) compared to basal activity (=100%) in the
presence of rimonabant. (B) Speciﬁcally bound [35S]GTPcS in percentage in the presence of 10 lM of the indicated ligands alone or together with 1 lM naltrindole in CHO-
mDOR cell membranes. Indicates the signiﬁcant alterations in speciﬁcally bound [35S]GTPcS (One-way ANOVA, Bonferroni’s Multiple Comparison post hoc test), compared
to basal activity (=100%) in the presence of rimonabant or DPDPE. ⁄Indicates the signiﬁcant reduction in the speciﬁcally bound [35S]GTPcS during DPDPE stimulation in the
presence of NTI compared to DPDPE alone. (C) Speciﬁcally bound [35S]GTPcS in percentage in the presence of increasing concentrations (1010 to 105 M) of rimonabant or
DPDPE in pCHO cell membranes. In case of rimonabant error bars are shorter than the points itself. The logEC50 value of rimonabant and the G-protein Emax value after
rimonabant activation are presented in the inset ﬁgure. ⁄denotes the signiﬁcant alterations of G-protein Emax value (unpaired t-test, two-tailed P value) compared to basal
activity (=100%) in the presence of rimonabant. Points and columns represent means ± S.E.M. for at least three experiments performed in triplicate. ‘‘Basal’’ on the X axis refers
to the points which did not contain ligands. The dotted line represents the receptors basal activity level, which was deﬁned as 100%. , ⁄⁄⁄: P < 0.001; : P < 0.05.
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and activator ligand potency in the micromolar range, when the
receptor is expressed in physiological conditions. Further on this
inhibitory action is independent from both cannabinoid receptors
and it is DOR speciﬁc.
4. Discussion
Rimonabant was the ﬁrst CB1 receptor antagonist/inverse ago-
nist to be developed, and it is still a perfect tool for antagonizing
CB1 related effects (for review see Pertwee, 2005). Later it turned
out that rimonabant had several non-cannabinoid related effects
such as decreasing alcohol intake, opiate self-administration and
increasing smoking cessation (for review see Foll and Goldberg,
2005). There is also evidence that rimonabant can interact with
several GPCRs and ion channels (for review see Pertwee, 2010).
This study focuses on the interaction between rimonabant and
DOR. The interaction was studied at ligand-receptor level in com-
petition binding experiments, and at the receptor-G-protein level
in functional [35S]GTPcS binding assays. These assays gather infor-
mation about the receptors ligand binding capacity (Schütz, 1991)
and functionality (Strange, 2010).
To our knowledge there has been only one paper so far studying
the direct effect of rimonabant on DOR (Kathmann et al., 2006) in
competition binding experiments and in saturation and kinetic
binding assays in cerebral cortical membranes with the DOR spe-
ciﬁc tritiated antagonist [3H]NTI. In competition binding experi-
ments they found that rimonabant inhibited [3H]NTI binding by
only 20%, while in our binding studies rimonabant decreased 50%
of [3H]Ile5,6deltorphin II and [3H]NTI total speciﬁc binding
(Fig. 1B). The diverse results in case of [3H]NTI can be partly ex-
plained by the different experimental conditions applied during
the assay (incubation time and temperature, ﬁnal volume etc.)
and by the applied CHO cell lines, which contained a homogeneous
population of overexpressed mouse DORs. CHO-mDOR cell mem-
branes insure near optimal conditions for a rimonabant–DOR inter-
action since no other opioid or even cannabinoid receptors were
present in the membrane preparation. Additionally in case of both
radioligands rimonabant reached an IC50 value in the micromolar
range (Fig. 1C), similar to our previously reported data on CHO-
MOR cell membranes (Zádor et al., 2012) and to other studies (Cin-
ar and Szücs, 2009; Fong et al., 2009; Kathmann et al., 2006). Inter-
estingly rimonabant also bound with an IC50 in the micromolar
range to other members of the GPCR family, such as adrenergic
or 5-HT6 receptors or to ion channels, like calcium, sodium and
potassium channels (for review see Pertwee, 2010). However rimo-
nabant also displaced the antagonist [3H]NTI in the subnanomolar
range (Fig. 1B) with a very high afﬁnity (Fig. 1C), which did not oc-
cur during the displacement of the agonist [3H]Ile5,6deltorphin II
(Fig. 1B and C). It is known that antagonists stabilize the receptors
in the inactive state, thus they prefer the inactive receptor form,
while agonists prefer the active receptor state, since they stabilize
the active form (Rosenbaum et al., 2009; Strange, 2002). Accord-
ingly in our competition binding experiments rimonabant may be-
have as an antagonist since it displaced [3H]NTI (which probably
stabilized the DOR to the inactive state) from the higher afﬁnity
Fig. 3. The effect of rimonabant on DOR G-protein activation in DPDPE-stimulated
[35S]GTPcS binding, in CHO-mDOR cell membranes. (A) Speciﬁcally bound
[35S]GTPcS in percentage in the presence of increasing concentrations (1010 to
105 M) of DPDPE in the absence or presence of the indicated rimonabant
concentrations. (B) The calculated Emax (maximal efﬁcacy) value of DOR G-protein.
(C) The calculated logEC50 (ligand potency) value of DPDPE. Points and columns
represent means ± S.E.M. for at least three experiments performed in triplicate.
⁄Indicates the signiﬁcant reduction in Emax and logEC50 values in the presence of
rimonabant compared to DPDPE alone (One-way ANOVA, Bonferroni’s Multiple
Comparison post hoc test). ‘‘Basal’’ on the X axis refers to the points which did not
contain DPDPE. The antilogarithm form of logEC50 (EC50) values are presented in
brackets. ⁄⁄⁄: P < 0.001; ⁄⁄: P < 0.01.
Fig. 4. The effect of rimonabant on DOR G-protein activation in DPDPE-stimulated
[35S]GTPcS binding in wild type and CB1/CB2 receptor double knock-out mouse
forebrain membranes. (A) Speciﬁcally bound [35S]GTPcS in percentage in the
presence of increasing concentrations (1010 to 105 M) of DPDPE in the absence or
presence of rimonabant. (B) The calculated Emax (maximal efﬁcacy) value of DOR G-
protein. (C) The calculated logEC50 (ligand potency) value of DPDPE. Points and
columns represent means ± S.E.M. for at least three experiments performed in
triplicate. ⁄Indicates the signiﬁcant reduction in Emax and logEC50 values in the
presence of rimonabant compared to DPDPE alone in wild type or in CB1/CB2
receptor double knock-out mouse (unpaired t-test, two-tailed P value). ‘‘Basal’’ on
the X axis refers to the points which did not contain activator ligands. The
antilogarithm form of logEC50 (EC50) values are presented in brackets. ⁄⁄⁄: P < 0.001;
⁄⁄: P < 0.01; ⁄: P < 0.05.
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binding site, which did not occur during the displacement of the
agonist [3H]Ile5,6deltorphin II (which probably stabilized the DOR
in the active state). In our previous paper similar results were ob-
served when rimonabant displaced the opioid antagonist [3H]nal-
oxone from the high afﬁnity binding site in CHO-MOR cell
membranes (Zádor et al., 2012). The high and low afﬁnity binding
sites were previously described in the GPCR superfamily among
the MORs as well (Baker and Hill, 2007; Krizsan et al., 1991).
It is well known that G-proteins have a constitutive activity (for
review see Seifert and Wenzel-Seifert, 2002) which can be further
modiﬁed upon ligand binding. In turn the altered basal activity ini-
tiates different types of signaling cascades (Hamm, 1998). For fur-
ther investigations we examined the impact of rimonabant on the
basal activity of the DORs G-protein, which can give us valuable
information about the binding character of rimonabant on DOR.
In our [35S]GTPcS binding assays rimonabant signiﬁcantly inhib-
ited receptor basal activity in CHO-mDOR membranes (Fig. 2A),
however we proved that this was not DOR related, since the effect
was not reversed by the DOR speciﬁc antagonist NTI (Fig. 2B) and it
also occurred in pCHO cell membranes (Fig. 2C) which did not ex-
press DORs (Figs. 1A and 2C). These ﬁndings also conﬁrms previous
reports in similar experimental conditions (Cinar and Szücs, 2009;
Seely et al., 2012). Therefore the agonistic (since rimonabant did
not enhance DOR G-protein basal activity) and inverse agonistic
character of rimonabant at DOR can be excluded. As regard to
the non-CB1 related inverse agonistic effect of rimonabant it has
been proven to be pertussis toxin sensitive and it has been
demonstrated in different types of brain tissues in several other
publications (Breivogel et al., 2001; Cinar and Szücs, 2009;
MacLennan et al., 1998; Sim-Selley et al., 2001).
Since rimonabant affected the DORs ligand binding, it raises the
possibility that it can also interfere with the receptors G-protein
activation during DOR speciﬁc agonist stimulation. Indeed, when
G-protein signaling was initiated with the cyclic enkephalin analog
DPDPE, rimonabant inhibited the maximal stimulation of the DORs
G-protein and also the potency of the stimulator ligand signiﬁ-
cantly (Fig. 3A–C). Moreover the inhibition occurred in the
micromolar concentration range, similarly as in direct afﬁnity
measurements in CHO-mDOR cell membranes. For comparison,
in CHO-MOR cell membrane preparations rimonabant (10 lM)
did not alter the DAMGO-stimulated (10 lM) G-protein activation
signiﬁcantly (Cinar and Szücs, 2009), in contrast in morphine-
induced [35S]GTPcS assays accomplished in CHO-MOR cell mem-
branes rimonabant reduced the potency of morphine (Seely et al.,
2012). Thus so far the inhibitory action of rimonabant on the
maximal stimulation of the DOR G-protein and on the potency
of the stimulator ligand in agonist-induced [35S]GTPcS
experiments indicates that rimonabant may behave as an antago-
nist on DOR.
The CHO cell line with homogeneous population of overexpres-
sed DOR is a useful tool to investigate the direct interaction be-
tween rimonabant and DOR, since there is no cannabinoid or
other opioid receptors in the system which can interact with
DOR, thus the direct effect of rimonabant can be measured more
accurately. However, it is well known that in physiological condi-
tions GPCR receptors often communicate with each other via over-
lapping signaling pathways or more even via heterodimerization
(González-Maeso, 2011; Hur and Kim, 2002; Jordan and Devi,
1999; Rozenfeld and Devi, 2011), which in addition alters there
functionality (Birdsall, 2010; Jordan and Devi, 1999). Taking this
into consideration we investigated the impact of rimonabant on
DOR G-protein activation in mouse forebrain, where the cannabi-
noid and opioid receptors are expressed in adequate quantity
(Gong et al., 2006; Howlett et al., 2002; Mansour et al., 1995;
Sim and Childers, 1997). According to our results, in micromolar
concentrations the inhibitory action of rimonabant also occurred
when the DOR and its G-protein were expressed in physiological
conditions (Fig. 4A–C). More importantly the inhibition was also
observed when neither cannabinoid receptors were expressed in
the forebrain (Fig. 4A–C); therefore it was a cannabinoid receptor
independent action, at least in the forebrain region. Previously
our group demonstrated a cannabinoid independent G-protein
inhibitory action of rimonabant on MOR, in the forebrain region
as well (Zádor et al., 2012). In another study, micromolar concen-
trations of rimonabant decreased the potency of the MOR stimula-
tor ligand CB1 receptor independently (Cinar and Szücs, 2009).
However the inhibitory action of rimonabant on DPDPE-stimulated
DOR G-protein activation might be due to the non-CB1 related in-
verse agonistic effect. To investigate this possibility we examined
L-epinephrine-induced G-protein activity in the presence of rimo-
nabant in CB1/CB2 receptor double knock-out mouse forebrain
membranes. According to our results micromolar concentrations
of rimonabant did not have any effect on adrenergic receptor G-
protein maximal activity or L-epinephrine potency during L-epi-
nephrine stimulation (Fig. 5A–C). Therefore we can conclude that
the decreased agonist mediated DOR G-protein activation by rimo-
nabant are truly DOR speciﬁc.
Thus rimonabant can directly inhibit DOR speciﬁc binding and
agonist-stimulated DOR G-protein efﬁcacy and potency. The mech-
anism behind these actions can be due to the antagonistic charac-
ter of rimonabant towards the DOR, which possibility is conﬁrmed
by our results in many levels: (1) the reduced speciﬁc binding of
the antagonist [3H]NTI in the subnanomolar concentration
range, (2) rimonabant did not enhanced the basal activity of
Fig. 5. The effect of rimonabant on AR G-protein activation in L-epinephrine-
stimulated [35S]GTPcS binding in CB1/CB2 receptor double knock-out mouse
forebrain membranes. (A) Speciﬁcally bound [35S]GTPcS in percentage in the
presence of increasing concentrations (1010 to 105 M) of L-epinephrine in the
absence or presence of rimonabant. (B) The calculated Emax (maximal efﬁcacy) value
of AR G-protein. (C) The calculated logEC50 (ligand potency) value of L-epinephrine.
Points and columns represent means ± S.E.M. for at least three experiments
performed in triplicate. ‘‘Basal’’ on the X axis refers to the points which did not
contain L-epinephrine. The antilogarithm form of logEC50 (EC50) values are
presented in brackets. AR: adrenergic receptor.
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DOR, therefore it did not behave as an agonist towards DOR, (3) the
inverse agonistic character can also be excluded since it was not a
DOR speciﬁc action, (4) the reduced potency of the stimulator
ligand and (5) the reduced Emax value of the DOR G-protein during
agonist stimulation, which were in addition DOR speciﬁc actions.
Further on the allosteric effect can also be excluded since
Kathmann and co-workers demonstrated previously that rimona-
bant did not show any allosteric properties on DOR in dissociation
kinetic studies (Kathmann et al., 2006). According to our previous
and Seely and co-workers study rimonabant is also believed to
have antagonistic properties towards the MOR (Seely et al., 2012;
Zádor et al., 2012), which was analyzed in receptor binding assays
together with in vivo (Seely et al., 2012) and in silico (Zádor et al.,
2012) experiments.
After chronic rimonabant treatment the plasma protein level of
the compound in humans is reported to be in the mid nanomolar
range (Cinar and Szücs, 2009; Henness et al., 2006; Kathmann
et al., 2006), which is ten times lower than the inhibitory concen-
tration range of rimonabant observed in DOR agonist binding and
DOR agonist stimulated G-protein activation. However there is
no data referring to the bioavailability of rimonabant or the tissue
distribution during chronic treatment. Additionally rimonabant is
a highly hydrophobic molecule, thus it can deposit in the fat tissue
and easily penetrate through the BBB (Rinaldi-Carmona et al.,
1995), also it has a long half-life (6–9 days with normal BMI and
16 days with higher than 30 kg/m2, see web reference), because
of its high plasma protein binding, which is almost 100% (see
web reference). Therefore it can be possible that rimonabant may
reach micromolar concentrations in peripheral tissues or even in
the brain during chronic treatment. Being aware of these informa-
tions the inhibitory actions of rimonabant on DOR function ob-
served in the micromolar range might have pharmacological
relevance. If so the antagonistic behavior of rimonabant on DOR
could partially explain the psychiatric side effects of the compound
during chronic treatments, since DOR antagonists are proved to
cause anxiogenic and depressive-like behavior (Perrine et al.,
2006; Saitoh et al., 2004). It is worth to note that the mediatory
role of KOR in the mood related side effects of rimonabant has been
demonstrated previously (Lockie et al., 2011).
In this study we demonstrated in in vitro experiments that
rimonabant can directly inhibit DOR function in the micromolar
range and that this inhibitory action is possibly due to its antago-
nist property towards DOR. Despite the high effective concentra-
tion, considering the pharmacological and chemical properties of
rimonabant this concentration range may have pharmacological
relevance.
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